



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> C07K 15/00, 15/06, 15/14 C07K 17/02, C09H 1/02 A61K 37/12	<b>A1</b>	<b>(11) International Publication Number:</b> WO 91/05802 <b>(43) International Publication Date:</b> 2 May 1991 (02.05.91)									
<b>(21) International Application Number:</b> PCT/US90/05903 <b>(22) International Filing Date:</b> 15 October 1990 (15.10.90)  <b>(30) Priority data:</b> <table border="0" style="width: 100%;"><tr><td style="width: 30%;">422,699</td><td style="width: 40%;">17 October 1989 (17.10.89)</td><td style="width: 30%;">US</td></tr><tr><td>483,913</td><td>22 February 1990 (22.02.90)</td><td>US</td></tr><tr><td>569,920</td><td>20 August 1990 (20.08.90)</td><td>US</td></tr></table> <b>(71) Applicant:</b> CREATIVE BIOMOLECULES, INC. [US/ US]; 35 South Street, Hopkinton, MA 01748 (US).  <b>(72) Inventors:</b> OPPERMAN, Hermann ; 25 Summer Hill Road, Medway, MA 02053 (US). KUBERASAMPATH, Thangavel ; 6 Spring Street, Medway, MA 02053 (US). RUEGER, David, C. ; 150 Edgemere Road, Apt. 4, West Roxbury, MA 02132 (US). OZKAYNAK, Engin ; 44 Purdue Drive, Milford, MA 01757 (US). PANG, Roy, H., L. ; 16 Kimberly Drive, Medway, MA 02053 (US).		422,699	17 October 1989 (17.10.89)	US	483,913	22 February 1990 (22.02.90)	US	569,920	20 August 1990 (20.08.90)	US	<b>(74) Agent:</b> PITCHER, Edmund, R.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BE (Euro- pean patent), CA, CH (European patent), DE (Euro- pean patent), DK (European patent), ES (European pa- tent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (Euro- pean patent), NL (European patent), SE (European pa- tent).  <b>Published</b> <i>With international search report.</i>
422,699	17 October 1989 (17.10.89)	US									
483,913	22 February 1990 (22.02.90)	US									
569,920	20 August 1990 (20.08.90)	US									
<b>(54) Title:</b> OSTEOGENIC DEVICES  <b>(57) Abstract</b>  Disclosed are 1) amino acid sequence data, structural features, and various other data characterizing a human osteogenic protein, OP1, 2) osteogenic devices comprising a heat treated xenogenic bone collagen matrix containing osteogenic protein, 3) methods of producing osteogenic proteins using recombinant DNA technology and 4) use of osteogenic devices to mimic the natural course of endochondral bone formation in mammals.											

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

-1-

OSTEOGENIC DEVICESReference to Related Applications

This application is a continuation-in-part of copending U.S. application Serial No. 422,699 filed October 17, 1989 entitled "Osteogenic Devices," and U.S. application Serial No. 483,913, filed February 22, 1990, entitled "Bone Collagen Matrix for Implants."

Background of the Invention

This invention relates to osteogenic devices, to genes encoding proteins which can induce new bone formation in mammals, and to methods for the production of these proteins in mammalian cells using recombinant DNA techniques. The invention also relates to matrix materials useful for allogenic or xenogenic implants and which act as a carrier of the osteogenic protein to induce new bone formation in mammals, and to bone and cartilage repair procedures using the osteogenic devices.

Mammalian bone tissue is known to contain one or more proteinaceous materials, presumably active during growth and natural bone healing, which

can induce a developmental cascade of cellular events resulting in endochondral bone formation. This active factor (or factors) has variously been referred to in the literature as bone morphogenetic or morphogenic protein, bone inductive protein, osteogenic protein, osteogenin, or osteoinductive protein.

The developmental cascade of bone differentiation consists of recruitment of mesenchymal cells, proliferation of progenitor cells, calcification of cartilage, vascular invasion, bone formation, remodeling, and finally marrow differentiation (Reddi (1981) Collagen Rel. Res. 1:209-226).

Though the precise mechanisms underlying these phenotypic transformations are unclear, it has been shown that the natural endochondral bone differentiation activity of bone matrix can be dissociatively extracted and reconstituted with inactive residual collagenous matrix to restore full bone induction activity (Sampath and Reddi (1981) Proc. Natl. Acad. Sci. USA 78:7599-7603). This provides an experimental method for assaying protein extracts for their ability to induce endochondral bone *in vivo*. Several species of mammals produce closely related protein as demonstrated by cross species implant experiments (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595).

The potential utility of these proteins has been recognized widely. It is contemplated that the availability of the protein would revolutionize

orthopedic medicine, certain types of plastic surgery, and various periodontal and craniofacial reconstructive procedures.

The observed properties of these protein fractions have induced an intense research effort in several laboratories directed to isolating and identifying the pure factor or factors responsible for osteogenic activity. The current state of the art of purification of osteogenic protein from mammalian bone is disclosed by Sampath et al. (1987) Proc. Natl. Acad. Sci. USA 80. Urist et al. (1984) Proc. Soc. Exp. Biol. Med. 173:194-199 disclose a human osteogenic protein fraction which was extracted from demineralized cortical bone by means of a calcium chloride-urea inorganic-organic solvent mixture, and retrieved by differential precipitation in guanidine-hydrochloride and preparative gel electrophoresis. The authors report that the protein fraction has an amino acid composition of an acidic polypeptide and a molecular weight in a range of 17-18 kD.

Urist et al. (1984) Proc. Natl. Acad. Sci. USA 81:371-375 disclose a bovine bone morphogenetic protein extract having the properties of an acidic polypeptide and a molecular weight of approximately 18 kD. The authors reported that the protein was present in a fraction separated by hydroxyapatite chromatography, and that it induced bone formation in mouse hindquarter muscle and bone regeneration in trephine defects in rat and dog skulls. Their method of obtaining the extract from bone results in ill-defined and impure preparations.

European Patent Application Serial No. 148,155, published October 7, 1985, purports to disclose osteogenic proteins derived from bovine, porcine, and human origin. One of the proteins, designated by the inventors as a P3 protein having a molecular weight of 22-24 kD, is said to have been purified to an essentially homogeneous state. This material is reported to induce bone formation when implanted into animals.

International Application No. PCT/087/01537, published January 14, 1988 (Int. Pub. No. WO88/00205), discloses an impure fraction from bovine bone which has bone induction qualities. The named applicants also disclose putative "bone inductive factors" produced by recombinant DNA techniques. Four DNA sequences were retrieved from human or bovine genomic or cDNA libraries and expressed in recombinant host cells. While the applicants stated that the expressed proteins may be bone morphogenic proteins, bone induction was not demonstrated, suggesting that the recombinant proteins are not osteogenic. The same group reported subsequently (Science, 242:1528, Dec. 1988) that three of the four factors induce cartilage formation, and postulate that bone formation activity "is due to a mixture of regulatory molecules" and that "bone formation is most likely controlled ... by the interaction of these molecules." Again, no bone induction was attributed to the products of expression of the cDNAs. See also Urist et al., EP0 212,474 entitled Bone Morphogenic Agents.

Wang et al. (1988) Proc. Nat. Acad. Sci. USA 85: 9484-9488, disclose the purification of a bovine bone morphogenetic protein from guanidine extracts of demineralized bone having cartilage and bone formation activity as a basic protein corresponding to a molecular weight of 30 kD determined from gel elution. Purification of the protein yielded proteins of 30, 18 and 16 kD which, upon separation, were inactive. In view of this result, the authors acknowledged that the exact identity of the active material had not been determined.

Wang et al. (1990) Proc. Nat. Acad. Sci. USA 87: 2220-2227 describes the expression and partial purification of one of the cDNA sequences described in PCT 87/01537. Consistent cartilage and/or bone formation with their protein requires a minimum of 600 ng of 50% pure material.

International Application No. PCT/89/04458 published April 19, 1990 (Int. Pub. No. WO90/003733), describes the purification and analysis of a family of osteogenic factors called "P3 OF 31-34". The protein family contains at least four proteins, which are characterized by peptide fragment sequences. The impure mixture P3 OF 31-34 is assayed for osteogenic activity. The activity of the individual proteins is neither assessed nor discussed.

It has been found that successful implantation of the osteogenic factors requires association of the proteins with a suitable carrier material capable of maintaining the proteins at an in vivo site of application. The carrier should be

biocompatible, biodegradable and porous enough to allow cell infiltration. The insoluble collagen particles remaining after guanidine extraction and delipidation of pulverized bone generally have been found effective in allogenic implants in some species. However, studies have shown that while osteoinductive proteins are useful cross species, the collagenous bone matrix generally used for inducing endochondral bone formation is species specific (Sampath and Reddi (1983) Proc. Nat. Acad. Sci. USA 80:6591-6594). Demineralized, delipidated, extracted xenogenic bone matrix carriers implanted in vivo invariably fail to induce osteogenesis, presumably due to inhibitory or immunogenic components in the bone matrix. Even the use of allogenic bone matrix in osteogenic devices may not be sufficient for osteoinductive bone formation in many species. For example, allogenic, subcutaneous implants of demineralized, delipidated monkey bone matrix is reported not to induce bone formation in the monkey. (Asperberg et al. (1988) J. Bone Joint Surg. (Br) 70-B:625-627).

U.S. 4,563,350, published January 7, 1986, discloses the use of trypsinized bovine bone matrix as a xenogenic matrix to effect osteogenic activity when implanted with extracted, partially purified bone-inducing protein preparations. Bone formation is said to require the presence of at least 5%, and preferably at least 10%, non-fibrillar collagen. The authors claim that removal of telopeptides which are responsible in part for the immunogenicity of collagen preparations is more suitable for xenogenic implants.



European Patent Application Serial No. 309,241, published 3/29/89, discloses a device for inducing endochondral bone formation comprising an osteogenic protein preparation, and a matrix carrier comprising 60-98% of either mineral component or bone collagen powder and 2-40% atelopeptide hypoinmunogenic collagen.

Deatherage et al. (1987) Collagen Rel. Res. 7:2225-2231, purport to disclose an apparently xenogenic implantable device comprising a bovine bone matrix extract that has been minimally purified by a one-step ion exchange column and reconstituted, highly purified human Type-I placental collagen.

U.S. 3,394,370, published 7/19/83, describes a matrix of reconstituted collagen purportedly useful in xenogenic implants. The collagen fibers are treated enzymatically to remove potentially immunogenic telopeptides (also the primary source of interfibril crosslinks) and are dissolved to remove associated non-collagen components. The matrix is formulated by dispersing the reconstituted collagen in acetic acid to form a disordered matrix of elementary collagen molecules that is then mixed with osteogenic factor and lyophilized to form a "semi-rigid foam or sponge" that is preferably crosslinked. The formulated matrix is not tested in vivo.

U.S. 4,172,128, published 10/23/79, describes a method for degrading and regenerating bone-like material of reduced immunogenicity, said to

be useful cross-species. Demineralized bone particles are treated with a swelling agent to dissolve any associated mucopolysaccharides (glycosaminoglycans) and the collagen fibers subsequently dissolved to form a homogenous colloidal solution. A gel of reconstituted fibers then can be formed using physiologically inert mucopolysaccharides and an electrolyte to aid in fibril formation.

It is an object of this invention to provide osteogenic devices comprising matrices containing dispersed osteogenic protein produced from recombinant DNA and capable of bone induction in allogenic and xenogenic implants. Another object is to provide recombinant osteogenic proteins expressed from mammalian cells and capable of inducing endochondral bone formation in mammals, including humans. Still another object is to provide genes encoding osteogenic proteins and methods for their production using recombinant DNA techniques. Yet another object is to provide a biocompatible, in vivo biodegradable matrix capable, in combination with an osteoinductive protein, of producing endochondral bone formation in mammals, including humans.

These and other objects and features of the invention will be apparent from the description, drawings, and claims which follow.

Summary of the Invention

This invention provides osteogenic proteins and devices which, when implanted in a mammalian body, can induce at the locus of the implant the full developmental cascade of endochondral bone formation including vascularization, mineralization, and bone marrow differentiation. The devices comprise a carrier material, referred to herein as a matrix, having the characteristics disclosed below, and containing dispersed osteogenic protein produced using recombinant DNA techniques and expressed from eukaryotic cells, preferably mammalian cells.

Preferred embodiments of the recombinant protein dispersed in the matrix disclosed herein closely mimic the physiological activity of native form protein extracted from natural sources and reconstituted in allogenic demineralized bone powder matrix material. The preferred proteins have a specific activity far higher than any biosynthetic material heretofore reported, an activity which, within the limits of precision of the activity assay, appears essentially identical to the substantially pure material produced as set forth in copending application Serial No. 179,406 filed April 8, 1988 (PCT US/89 01453). Thus, this application discloses how to make and use osteogenic devices which induce the full developmental cascade of endochondral bone formation essentially as it occurs in natural bone healing.

A key to these developments was the elucidation of amino acid sequence and structure data

of native osteogenic protein. A protocol was developed which results in retrieval of active, substantially pure osteogenic protein from mammalian bone having a half-maximum bone forming activity of about 0.8 to 1.0 ng per mg of implant. The availability of the material enabled the inventors to elucidate all structural details of the protein necessary to achieve bone formation. Knowledge of the protein's amino acid sequence and other structural features enabled the identification and cloning of native genes.

Consensus DNA sequences based on partial sequence data and observed homologies with regulatory proteins disclosed in the literature were used as probes for extracting genes encoding osteogenic protein from genomic and cDNA libraries. One of the consensus sequence probes isolated a previously unidentified DNA sequence, portions of which, when ligated, encoded a protein comprising a region capable of inducing endochondral bone formation when properly modified, incorporated in a suitable matrix, and implanted as disclosed herein. The protein, referred to herein as OP1, as well as various truncated forms and fusion constructs, has been expressed in E. coli and various mammalian cells from the full length cDNA sequence and various truncated synthetic DNAs, and has been discovered to exhibit osteogenic activity as a homodimer or as a heterodimer with BMP2, another osteogenic protein extracted from human DNA libraries with the consensus sequence probes.

Characterization of the OP1 gene and identification of the DNA and amino acid sequence necessary for activity has allowed expression of the gene in mammalian cells. Mammalian cell expression of recombinant proteins, particularly mammalian proteins intended for therapeutic use, is generally thought to yield proteins having a structure most like that of the natural material. This is particularly true for secreted proteins which require particular post-translational modifications, such as glycosylation, which are not carried out in procaryotic systems. While expression of the OP1 gene in E. coli has shown that the unglycosylated form of the protein has osteogenic activity, there may be other as yet undetermined functions for the oligosaccharides, relating to protein stability, solubility, or immunogenicity, for example. In addition, purification of proteins secreted into culture media provide an alternative to extraction of induced proteins from procaryotic inclusion bodies.

Mammalian cell expression of the gene also has allowed determination of the N-terminus of the mature protein. The amino acid sequence of what is believed to be the mature form of OP1 is (Seq. ID No. 1):

OPl-18

```

1      10
S T G S K Q R S Q N R S K T P
      20      30
K N Q E A L R M A N V A E N S
      40
S S D Q R Q A C K K H E L Y V
      50      60
S F R D L G W Q D W I I A P E
      70
G Y A A Y Y C E G E C A F P L
      80      90
N S Y M N A T N H A I V Q T L
      100
V H F I N P E T V P K P C C A
      110      120
P T Q L N A I S V L Y F D D S
      130
S N V I L K K Y R N M V V R A
C G C H.

```

Recombinantly-produced OPl also is active in several forms truncated at the protein's N-terminus. One main species of truncated OPl is (Seq. ID No. 2):

OPl-16S

```

      8      10
      S Q N R S K T P
      20      30
K N Q E A L R M A N V A E N S
      40
S S D Q R Q A C K K H E L Y V
      50      60
S F R D L G W Q D W I I A P E
      70
G Y A A Y Y C E G E C A F P L
      80      90
N S Y M N A T N H A I V Q T L
      100
V H F I N P E T V P K P C C A
      110      120
P T Q L N A I S V L Y F D D S
      130
S N V I L K K Y R N M V V R A
C G C H.

```

Four other active shorter OPl sequences  
are:

OPl-16L (Seq. ID No. 3)

```

                21                               30
                L R M A N V A E N S
                40
S S D Q R Q A C K K H E L Y V
                50                               60
S F R D L G W Q D W I I A P E
                70
G Y A A Y Y C E G E C A F P L
                80                               90
N S Y M N A T N H A I V Q T L
                100
V H F I N P E T V P K P C C A
                110                               120
P T Q L N A I S V L Y F D D S
                130
S N V I L K K Y R N M V V R A
C G C H ;

```

OPl-16M (Seq. ID No. 4)

```

                23                               30
                M A N V A E N S
                40
S S D Q R Q A C K K H E L Y V
                50                               60
S F R D L G W Q D W I I A P E
                70
G Y A A Y Y C E G E C A F P L
                80                               90
N S Y M N A T N H A I V Q T L
                100
V H F I N P E T V P K P C C A
                110                               120
P T Q L N A I S V L Y F D D S
                130
S N V I L K K Y R N M V V R A
C G C H ;

```

OP1-16A (Seq. ID. No. 5)

24  
 A N V A E N S 30  
 40  
 S S D Q R Q A C K K H E L Y V  
 50  
 S F R D L G W Q D W I I A P E 60  
 70  
 G Y A A Y Y C E G E C A F P L  
 80  
 N S Y M N A T N H A I V Q T L 90  
 100  
 V H F I N P E T V P K P C C A  
 110  
 P T Q L N A I S V L Y F D D S 120  
 130  
 S N V I L K K Y R N M V V R A  
 C G C H ; and

OP1-16V (Seq. ID. No. 6)

V A E N S 30  
 40  
 S S D Q R Q A C K K H E L Y V  
 50  
 S F R D L G W Q D W I I A P E 60  
 70  
 G Y A A Y Y C E G E C A F P L  
 80  
 N S Y M N A T N H A I V Q T L 90  
 100  
 V H F I N P E T V P K P C C A  
 110  
 P T Q L N A I S V L Y F D D S 120  
 130  
 S N V I L K K Y R N M V V R A  
 C G C H.



These 6 species of OP1 have been tested for osteogenic activity in vivo and all have been shown to induce endochondral bone formation in a dose-dependent manner when implanted in a mammal in association with a suitable matrix. The specific activity of these species is close to that of the substantially pure, naturally-sourced osteogenic protein. Moreover, these proteins mimic the activity of the naturally-sourced material more closely than other osteogenic protein preparations heretofore reported.

Recombinantly produced OP1 is expressed as a glycosylated homodimer in mammalian cells. Homodimers of OP1-18 have an apparent molecular weight of about 36 kD, when oxidized, and about 18 kD when reduced, as determined by SDS-PAGE gels. OP1-16S, OP1-16V, OP1-16M, OP1-16A and OP1-16L have an apparent molecular weight of about 16kD, when reduced, and homodimers of these proteins, as well as heterodimers with OP1-18 have an apparent molecular weight within the range of about 30-36 kD when oxidized, as determined by SDS-PAGE gels. In the reduced state, these proteins have no detectable osteogenic activity.

OP1 now has been expressed in a number of different mammalian cells, all of which glycosylate and process the protein after translation. While the precise structure of the oligosaccharide side chains may vary among the different cell lines, in all cases the expressed sequence is osteogenically active in a specific and dose dependent manner.

The invention is not limited to those specific constructs. Thus, the osteogenic proteins of this invention may include forms having varying glycosylation patterns, varying N-termini, a family of related proteins having regions of amino acid sequence homology, and active truncated or mutated forms of the native amino acid sequence, produced by expression of recombinant DNA in eucaryotic host cells. Active sequences useful in an osteogenic device of this invention is envisioned to include osteogenic proteins having at least a 70% sequence homology, preferably at least 80%, with the amino acid sequence of OP1-16V. This includes longer forms of the protein, as well as allelic variants and muteins.

Thus, in view of this disclosure, skilled genetic engineers can isolate genes from cDNA or genomic libraries which encode appropriate amino acid sequences, or construct DNAs from oligonucleotides, and then can express them in various types of eucaryotic host cells to produce large quantities of active proteins capable of inducing bone formation in mammals, including humans.

The osteogenic proteins are useful in clinical applications in conjunction with a suitable delivery or support system (matrix). The matrix comprises biocompatible, protein-extracted, mineral-free, delipidated, insoluble Type-I bone collagen particles which may be allogenic or xenogenic to the host. The particles preferably are treated with a fibril-modifying agent such as hot water or other fibril-modifying solvents, to alter

the particle morphology, i.e., to increase the intraparticle porosity and the surface area of the particles. The particles are packed together to form the matrix. The spaces among the particles must be of a dimension to permit progenitor cell migration and subsequent cell differentiation and proliferation. The particle size should be within the range of 70 - 850  $\mu\text{m}$ , preferably 150 $\mu\text{m}$  - 420 $\mu\text{m}$ . The matrix may be fabricated by close packing the particles into a shape spanning the bone defect, or by otherwise shaping the packed particles as desired. The matrix is biocompatible (non-inflammatory) and biodegradable in vivo, and serves as a "temporary scaffold" and substratum for recruitment of migratory progenitor cells, and as a base for their subsequent anchoring and proliferation. As disclosed herein, the matrix may be combined with osteogenic protein to induce endochondral bone formation reliably and reproducibly in a mammalian body.

The development of this matrix material resulted from the discovery of key features required for successful implantation of xenogenic bone matrix and osteogenic protein. Studies indicated that osteogenic devices comprising substantially pure osteogenic protein and allogenic demineralized, delipidated protein-extracted bone matrices must have interstices dimensioned to permit the influx, proliferation and differentiation of migratory progenitor cells. It was also observed that osteogenic devices comprising xenogenic bone matrices induce little or no endochondral bone formation in vivo. The absence of bone formation by xenogenic

matrices generally has been thought to be due to an immunogenic or inhibitory response to components still present in the matrix (e.g., the collagen telopeptides or associated non-collagenous glycoproteins.)

It has now been discovered that the overall specific particle surface area (surface area/unit mass), the degree of porosity and micropitting, and the size of the micropits and pores of the matrix particles is important for successful xenogenic implants, and even for allogenic implants of certain species.

Panels A and B of FIGURE 1 are scanning electron micrographs showing the particle structure of demineralized, guanidine-extracted bone matrix from rat and calf, respectively. As can be seen from the SEMs, there is a significantly greater inherent porosity, or surface area, in rat bone matrix than in bovine bone matrix. It has been discovered that increasing the porosity and intraparticle surface area of bone matrix can promote osteogenic induction as evidenced by rat collagenous bone matrix implants. This is achieved by treating collagenous bone matrix with certain solvents or heat so as to alter its morphology. Agents suitable for this purpose are disclosed herein and are termed collagen fibril-modifying agents.

Thus, one aspect of this invention includes osteogenic devices comprising matrices which have been treated to increase the surface area and porosity of matrix collagen particles substantially.

The currently preferred fibril-modifying agent useful in the osteogenic devices of this invention is a heated aqueous medium, most preferably water. Heating demineralized delipidated guanidine extracted bone collagen in water at high temperature ( $37^{\circ}$ - $65^{\circ}$ , preferably  $45^{\circ}$ - $60^{\circ}\text{C}$ ) for approximately one hour is generally sufficient to achieve the desired surface morphology. Although the mechanism is not clear, it is hypothesized that the heat treatment alters the collagen fibrils, resulting in an increase in the particle's surface area. Thus, bone matrix may be treated at various elevated temperatures in water (1g/30ml) with stirring and then filtered. Treatment of insoluble collagen in water by increasing temperature results initially in a melting transition ( $T_m$ ), the temperature required to go from one-quarter to three quarters of the total transition from helical structure to non-helical. Thereafter the fibrils will shrink abruptly a fraction of length at some higher temperature, designated as the shrinkage temperature ( $T_s$ ).  $T_s$  is normally higher than  $T_m$ , reflecting the added stability contributed by molecular packing. At pHs below approximately 5, both the  $T_m$  and  $T_s$  values decrease for heated collagen.

Examination of solvent treated bone collagenous matrix shows that demineralized guanidine-extracted xenogenic bovine bone comprises a mixture of additional materials and that extracting these materials can improve matrix properties. Chromatographic separation of components in the extract, followed by addition back to active matrix of the various extract fractions corresponding to the

chromatogram peaks, indicates that there is a fraction which can inhibit the osteoinductive effect. The identity of the substance or substances in this inhibiting fraction has not as yet been determined. In one aspect of this invention, a matrix is provided comprising Type-I bone collagen particles of the type described above, further characterized in that they are depleted in this inhibiting component.

In view of this disclosure, one skilled in the art can create a biocompatible matrix of choice having a desired porosity or surface microtexture useful in the production of osteogenic devices, and useful in other implantable contexts, e.g., as a packing to promote bone induction, or as a biodegradable sustained release implant.

The osteogenic proteins and implantable osteogenic devices disclosed herein will permit the physician to obtain optimal predictable bone formation to correct, for example, acquired and congenital craniofacial and other skeletal or dental anomalies (Glowacki et al. (1981) Lancet 1:959-963). The devices may be used to induce local endochondral bone formation in non-union fractures as demonstrated in animal tests, and in other clinical applications including periodontal applications where bone formation is required. Another potential clinical application is in cartilage repair, for example, in the treatment of osteoarthritis.

Brief Description of the Drawing

The foregoing and other objects of the invention, the various features thereof, as well as the invention itself, may be more fully understood from the following description, when read together with the accompanying drawings, in which:

FIGURE 1A and 1B are scanning electron micrographs (5000X) of demineralized, delipidated (A) rat bone collagen particles, and (B) bovine bone collagen particles;

FIGURE 2-1 and 2-2 represent the full length cDNA and encoded amino acid sequence of the prepro form of human OP1 protein (Seq. ID No. 7);

FIGURE 3A through 3F are restriction maps of various expression vectors designed for the mammalian cell expression of OP1;

FIGURE 4 is a photoreproduction of western blots (immunoblots) comparing OP1 expressed from: COS cells - (A) pH717, (B) pH731; CHO cells - (C) pH754, (D) pH752; and BSC cells - (E) pH717, (F) pH24;

FIGURE 5A-C are (1) elution profiles and (2) photoreproductions of SDS-PAGE gels expressed from BSC cells and purified (in order) on: (A) S-Sepharose, (B) phenyl-Sepharose, and (c) C-18 columns;

FIGURE 6 is a photoreproduction of SDS-PAGE gels of OP1 purified from BSC cells, comparing the intact dimer under oxidized conditions (36 kD, lane 1) and the corresponding monomer, after reduction with dithiothreitol (18kD, lane 5), with molecular weight standards (lanes 2-4);

FIGURE 7A through 7D are scanning electron micrographs (approx. 1000X) of demineralized, delipidated bovine bone matrix heat treated in water at (A) 37° C, (B) 45° C, (C) 55° C, and (D) 65° C;

FIGURE 8 is a 214 nm absorbance tracing of the extract isolated from hot water-treated bovine matrix, identifying the inhibitory effect of individual fractions on in vivo bone formation;

FIGURE 9A and 9B are bar graphs showing the inhibitory effect of hot water-treated matrix extract on OP1 activity, as measured by (A) alkaline phosphatase activity and (B) calcium content in day 12 implants, vs. increasing concentration of extract solvent;

FIGURE 10A-F are photomicrographs (220x) of allogenic implants of OP1 expressed from COS, BSC and CHO cells, and which follow the developmental cascade of endochondral bone osteogenesis;

FIGURE 11 is a photomicrograph showing the histology (day 12) of a xenogenic implant of this invention using OP1 expressed from BSC cells and hot water-treated xenogenic bovine matrix;



FIGURE 12 describes the dose dependence of osteogenic implants for day 12 implants, as determined by alkaline phosphatase activity and calcium content, for allogenic implants containing OP1 expressed from COS, BSC and CHO cells; and

FIGURE 13A and 13B are bar graphs showing the dose dependence of OP1 expressed in COS and BSC cells, as measured by (A) alkaline phosphatase activity and (B) calcium content in xenogenic implants (day 12), vs increasing concentration of protein (dose curve in ng).

Description

Purification protocols first were developed which enabled isolation of the osteogenic protein present in crude protein extracts from mammalian bone. (See PCT US 89/01453, and U.S. Serial No. 179,406 filed April 8, 1988). The development of the procedure, coupled with the availability of fresh calf bone, enabled isolation of substantially pure bovine osteogenic protein (BOP). BOP was characterized significantly; its ability to induce cartilage and ultimately endochondral bone growth in cat, rabbit, and rat were demonstrated and studied; it was shown to be able to induce the full developmental cascade of bone formation previously ascribed to unknown protein or proteins in heterogeneous bone extracts. This dose dependent and highly specific activity was present whether or not the protein was glycosylated (see U.S. Serial No. 232,630 filed 8/15/88 and Sampath et al., (1990) J. Biol. Chem. 265: pp. 13198-13205). Sequence data obtained from the bovine materials suggested probe designs which were used to isolate human genes. The OP human counterpart proteins have now been expressed and extensively characterized.

These discoveries enabled preparation of DNAs encoding totally novel, non-native protein constructs which individually as homodimers and combined with other species as heterodimers are capable of producing true endochondral bone (see PCT 89/01469, filed 4/7/89 and US Serial No. 315,342, filed 2/23/89). They also permitted expression of the natural material, truncated forms, muteins,

analogs, fusion proteins, and various other variants and constructs, from cDNAs and genomic DNAs retrieved from natural sources or from synthetic DNA produced using the techniques disclosed herein and using automated, commercially available equipment. The DNAs may be expressed using well established molecular biology and recombinant DNA techniques in procaryotic or eucaryotic host cells, and may be oxidized and refolded in vitro if necessary, to produce biologically active protein.

One of the DNA sequences isolated from genomic and cDNA libraries encoded a previously unidentified gene, referred to herein as OP1. The protein encoded by the isolated DNA was identified originally by amino acid homology with proteins in the TGF- $\beta$  family. Consensus splice signals were found where amino acid homologies ended, designating exon-intron boundaries. Three exons were combined to obtain a functional TGF- $\beta$ -like domain containing seven cysteines. (See, for example, U.S. Serial No. 315,342 filed 2/23/80, or Ozkaynak, E. et al., (1990) EMBO. 9: pp. 2085-2093).

The full-length cDNA sequence for OP1, including the amino acid sequence it encodes, is represented in Figure 2. This full length cDNA sequence of OP1, as well as various truncated forms of the gene, and fused genes, have been expressed in E. coli and shown to have osteogenic activity when implanted in a mammal in association with a matrix.

The native form protein is expressed originally in a "prepro" form which includes a signal

peptide sequence for appropriate secretion of the protein. The signal peptide cleavage site is underlined in Figure 2. Removal of the signal peptide yields the "pro" form of the protein, which is processed upon secretion to yield the mature sequence. The cleavage site yielding the mature sequence is indicated by an arrow in Figure 2. The amino acid sequence of what is believed to be the mature form is (Seq. ID No. 1):

OP1-18

```

1          10
S  T  G  S  K  Q  R  S  Q  N  R  S  K  T  P
          20          30
K  N  Q  E  A  L  R  M  A  N  V  A  E  N  S
          40
S  S  D  Q  R  Q  A  C  K  K  H  E  L  Y  V
          50          60
S  F  R  D  L  G  W  Q  D  W  I  I  A  P  E
          70
G  Y  A  A  Y  Y  C  E  G  E  C  A  F  P  L
          80          90
N  S  Y  M  N  A  T  N  H  A  I  V  Q  T  L
          100
V  H  F  I  N  P  E  T  V  P  K  P  C  C  A
          110          120
P  T  Q  L  N  A  I  S  V  L  Y  F  D  D  S
          130
S  N  V  I  L  K  K  Y  R  N  M  V  V  R  A
C  G  C  H.

```

Both the pro form and prepro form, when properly dimerized, folded, adsorbed on a matrix, and implanted, display osteogenic activity, presumably due to proteolytic degradation resulting in cleavage and generation of mature form protein or active truncated analogs.

Active OP1 can also be purified in a truncated form, missing part of the protein's N terminus. One active truncated form of OP1 is (Seq. ID No. 2):

OP1-16S

```

      8      10
      S Q N R S K T P
20 K N Q E A L R M A N V A E N S 30
      40
S S D Q R Q A C K K H E L Y V
      50      60
S F R D L G W Q D W I I A P E
      70
G Y A A Y Y C E G E C A F P L
      80      90
N S Y M N A T N H A I V Q T L
      100
V H F I N P E T V P K P C C A
      110      120
P T Q L N A I S V L Y F D D S
      130
S N V I L K K Y R N M V V R A
C G C H.

```

Four other active truncated forms of OP1 are:

OP1-16L (Seq. ID. No. 3)

```

21 L R M A N V A E N S 30
      40
S S D Q R Q A C K K H E L Y V
      50      60
S F R D L G W Q D W I I A P E
      70
G Y A A Y Y C E G E C A F P L
      80      90
N S Y M N A T N H A I V Q T L
      100
V H F I N P E T V P K P C C A
      110      120
P T Q L N A I S V L Y F D D S
      130
S N V I L K K Y R N M V V R A
C G C H;

```

OP1-16M (Seq. ID. No. 4)

23 30  
 M A N V A E N S  
 40  
 S S D Q R Q A C K K H E L Y V  
 50 60  
 S F R D L G W Q D W I I A P E  
 70  
 G Y A A Y Y C E G E C A F P L  
 80 90  
 N S Y M N A T N H A I V Q T L  
 100  
 V H F I N P E T V P K P C C A  
 110 120  
 P T Q L N A I S V L Y F D D S  
 130  
 S N V I L K K Y R N M V V R A  
 C G C H ;

OP1-16A (Seq. ID. No. 5)

24 30  
 A N V A E N S  
 40  
 S S D Q R Q A C K K H E L Y V  
 50 60  
 S F R D L G W Q D W I I A P E  
 70  
 G Y A A Y Y C E G E C A F P L  
 80 90  
 N S Y M N A T N H A I V Q T L  
 100  
 V H F I N P E T V P K P C C A  
 110 120  
 P T Q L N A I S V L Y F D D S  
 130  
 S N V I L K K Y R N M V V R A  
 C G C H ; and

OP1-16V (Seq. ID. No. 6)

```

                26          30
                V  A  E  N  S
          40
S  S  D  Q  R  Q  A  C  K  K  H  E  L  Y  V
          50
S  F  R  D  L  G  W  Q  D  W  I  I  A  P  E
          60
          70
G  Y  A  A  Y  Y  C  E  G  E  C  A  F  P  L
          80
N  S  Y  M  N  A  T  N  H  A  I  V  Q  T  L
          90
          100
V  H  F  I  N  P  E  T  V  P  K  P  C  C  A
          110
P  T  Q  L  N  A  I  S  V  L  Y  F  D  D  S
          120
          130
S  N  V  I  L  K  K  Y  R  N  M  V  V  R  A
C  G  C  H .

```

Given the foregoing amino acid and DNA sequence information, various DNAs can be constructed which encode at least the minimal active domain of OP1, and various analogs thereof, as well as fusion proteins, other truncated forms of the mature proteins, and similar constructs. These DNAs can be produced by those skilled in the art using well known DNA manipulation techniques involving genomic and cDNA isolation, construction of synthetic DNA from synthesized oligonucleotides, and cassette mutagenesis techniques. 15-100mer oligonucleotides may be synthesized on a Biosearch DNA Model 8600 Synthesizer, and purified by polyacrylamide gel electrophoresis (PAGE) in Tris-Borate-EDTA buffer. The DNA may then be electroeluted from the gel. Overlapping oligomers may be phosphorylated by T4 polynucleotide kinase and ligated into larger blocks which may also be purified by PAGE.

The cDNA or synthetic DNA then may be integrated into an expression vector and transfected into an appropriate host cell for protein expression. The host may be a procaryotic or eucaryotic cell since the former's inability to glycosylate protein will not destroy the protein's osteogenic activity. Useful host cells include E. coli, Saccharomyces, the insect/baculovirus cell system, myeloma cells, and various mammalian cells. The protein of this invention preferably is expressed in mammalian cells, as disclosed herein. The vector additionally may encode various sequences to promote correct expression of the recombinant protein, including transcription promoter and termination sequences, enhancer sequences, preferred ribosome binding site sequences, preferred mRNA leader sequences, preferred signal sequences for protein secretion, and the like. The DNA sequence encoding the gene of interest also may be manipulated to remove potentially inhibiting sequences or to minimize unwanted secondary structure formation. The recombinant osteogenic protein also may be expressed as a fusion protein. After being translated, the protein may be purified from the cells themselves or recovered from the culture medium. All biologically active protein forms comprise dimeric species joined by disulfide bonds or otherwise associated, produced by oxidizing and refolding one or more of the various recombinant proteins within an appropriate eucaryotic cell or in vitro after expression of individual subunits.

As stated earlier, it is generally held that recombinant production of mammalian proteins for



therapeutic uses are preferably expressed in mammalian cell culture systems in order to produce a protein whose structure is most like that of the natural material. Recombinant protein production in mammalian cells requires the establishment of appropriate cells and cell lines that are easy to transfect, are capable of stably maintaining foreign DNA with an unrearranged sequence, and which have the necessary cellular components for efficient transcription, translation, post-translation modification, and secretion of the protein. In addition, a suitable vector carrying the gene of interest also is necessary. DNA vector design for transfection into mammalian cells should include appropriate sequences to promote expression of the gene of interest as described supra, including appropriate transcription initiation, termination, and enhancer sequences, as well as sequences that enhance translation efficiency, such as the Kosak consensus sequence. Preferred DNA vectors also include a marker gene and means of amplifying the copy number of the gene of interest.

Substantial progress in the development of mammalian cell expression systems has been made in the last decade and many aspects of the system are well characterized. A detailed review of the state of the art of the production of foreign proteins in mammalian cells, including useful cells, protein expression-promoting sequences, marker genes, and gene amplification methods, is disclosed in Bendig, Mary M., (1988) Genetic Engineering, 7:91-127.

Briefly, among the best characterized transcription promoters useful for expressing a foreign gene in a particular mammalian cell are the SV40 early promoter, the adenovirus promoter (AdMLP), the mouse metallothionein-I promoter (mMT-I), the Rous sarcoma virus (RSV) long terminal repeat (LTR), the mouse mammary tumor virus long terminal repeat (MMTV-LTR), and the human cytomegalovirus major intermediate-early promoter (hCMV). The DNA sequences for all of these promoters are known in the art and are available commercially.

One of the better characterized methods of gene amplification in mammalian cell systems is the use of the inducible DHFR gene in a dhfr- cell line. Generally, the DHFR gene is provided on the vector carrying the gene of interest, and induction by addition of the cytotoxic drug methotrexate amplifies the DHFR gene copy number, as well as that of the associated gene of interest. DHFR as an inducible, amplifying marker gene in transfected chinese hamster ovary cell lines (CHO cells) is particularly well characterized in the art. Other genes useful as inducible gene amplifiers include the adenosine deaminase (ADA) and glutamine synthetase (GS) genes.

The choice of cells/cell lines is also important and depends on the needs of the experimenter. Monkey kidney cells (COS) provide high levels of transient gene expression, providing a useful means for rapidly testing vector construction and the expression of cloned genes. COS cells are transfected with a simian virus 40 (SV40) vector carrying the gene of interest. The transfected COS

cells eventually die, thus preventing the long term production of the desired protein product. However, transient expression does not require the time consuming process (often several weeks) required for the development of a stable cell line.

Among established cell lines, CHO cells may be the best characterized to date. They also are capable of expressing proteins from a broad range of cell types. The general applicability of CHO cells and its successful production for a wide variety of human proteins in unrelated cell types emphasizes the underlying similarity of all mammalian cells. Thus, while the glycosylation pattern on a recombinant protein produced in a mammalian cell expression system may not be identical to the natural protein, the differences in oligosaccharide side chains are often not essential for biological activity of the expressed protein.

Methods for expressing and purifying recombinant OPl from a variety of mammalian cells, the nature of the xenogenic matrix, and other material aspects concerning the nature, utility, and how to make and how to use the subject matter claimed will be further understood from the following, which constitutes the best method currently known for practicing the invention.

#### I. RECOMBINANT PROTEIN EXPRESSION IN MAMMALIAN CELLS

Several different mammalian cell expression systems have been used to express recombinant OPl

proteins of this invention. In particular, COS cells are used for the rapid assessment of vector construction and gene expression, using an SV40 vector to transfect the DNA sequence into COS cells. Stable cell lines are developed using CHO cells (chinese hamster ovary cells) and a temperature-sensitive strain of BSC cells (simian kidney cells, BSC40-tsA58, (1988) Biotechnology 6: 1197-1196) for the long term production of OPl. Two different promoters are used to transcribe OPl: the CMV promoter, boosted by the enhancer sequence from the Rous sarcoma virus LTR, and the mMT promoter (mouse metallothionein promoter). Several selection marker genes also are used, namely, neo (neomycin) and DHFR. The DHFR gene also may be used as part of a gene amplification scheme for CHO cells. Another gene amplification scheme relies on the temperature sensitivity (ts) of BSC40-tsA58 cells transfected with an SV40 vector. Temperature reduction to 33°C stabilizes the ts SV40 T antigen which leads to the excision and amplification of the integrated transfected vector DNA, thereby also amplifying the associated gene of interest.

Stable cell lines were established for CHO cells as well as BSC40-tsA58 cells (hereinafter referred to as "BSC cells"). The various cells, cell lines and DNA sequences chosen for mammalian cell expression of the OPl proteins of this invention are well characterized in the art and are readily available. Other promoters, selectable markers, gene amplification methods and cells also may be used to express the OPl proteins of this invention, as well as other osteogenic proteins. Particular details of

the transfection, expression, and purification of recombinant proteins are well documented in the art and are understood by those having ordinary skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in mammalian cell expression systems can be found in a number of texts and laboratory manuals in the art, such as, for example, Current Protocols in Molecular Biology, F.M. Ausubel et al., ed., John Wiley & Sons, New York 1987.

#### 1. Exemplary Expression Vectors

Figure 3 discloses restriction maps of various exemplary expression vectors designed for OP1 expression in mammalian cells. Each of these vector constructs employs a full-length cDNA sequence originally isolated from a human cDNA library (human placenta) and subsequently cloned into a conventional pUC vector (pUC-18) using pUC polylinker sequences at the insertion sites. The OP1 cDNA fragment cloned into each of these constructs is either the intact SmaI-BamHI OP1 cDNA fragment depicted in Figure 2 (Seq. ID No.7), or modifications of this fragment where the flanking non-coding 5' and/or 3' sequences have been trimmed back, using standard molecular biology methodology. Each vector also employs an SV40 origin of replication (ori), useful for mediating plasmid replication in primate cells (e.g., COS and BSC cells). In addition, the early SV40 promoter is used to drive transcription of marker genes on the vector (e.g., neo and DHFR).

The pH717 expression vector (Fig. 3A) contains the neomycin (neo) gene as an inducible

selection marker. This marker gene is well characterized in the art and is available commercially. Alternatively, other selectable markers may be used. The particular vector used to provide the neo gene DNA fragment for pH717 may be obtained from Clontech, Inc., Palo Alto, CA (pMAM-neo-blue). In pH717, OPl DNA transcription is driven by the CMV promoter, boosted by the RSV-LTR and MMTV-LTR (mouse mammary tumor virus) enhancer sequences. These sequences are known in the art, and are available commercially. For example, vectors containing this promoter/enhancer sequence may be obtained from Invitrogen Inc., San Diego, CA, (e.g., pCDM8).

Expression vector pH731 (Fig.3B), utilizes the SV40 late promoter to drive OPl transcription. As indicated above, the sequence and characteristics of this promoter also are well known in the art. Alternatively, pH731 may be generated by inserting the SmaI-BamHI fragment of OPl into pEUK-C1 (Clontech, Inc., Palo Alto, CA).

The pH754 expression vector (Fig. 3C) contains the DHFR sequence as both a selection marker and as an inducible gene amplifier. OPl is under CMV control. The DNA sequence for DHFR and is well characterized in the art, and is available commercially. Alternatively, pH754 may be generated from pMAM-neo (Clontech, Inc., Palo Alto, CA) by replacing the neo gene (BamHI digest) with a BamHI fragment containing the DHFR gene (e.g., obtained from pSV5-dhfr (ATCC #37148)). OPl DNA then can be inserted into the polylinker site downstream of the MMTVLTR sequence (mouse mammary tumor virus LTR),

yielding pH752 (Fig. 3D). The CMV promoter sequence then may be inserted into pH752 (opened at ClaI-NheI) as a ClaI-XbaI fragment (e.g., from pMAM-neo blue, Clontech, Inc.).

The pW24 vector (Fig. 3E), is essentially identical in sequence to p754, except that neo is used as the marker gene (see pH717), in place of DHFR.

Similarly, pH783 (Fig. 3F) contains the amplifiable marker DHFR, but here OP1 is under mMT (mouse metallothionein promoter) control. The mMT promoter is well characterized in the art and is available commercially. Alternatively, a ClaI-NheI fragment containing the mMT promoter sequence (available from Allegro Nichols Institute Diagnostics, San Juan Capistrano, CA) can be inserted into pH752 to generate pH783.

All vectors tested are stable in the various cells used to express OP1, and provide a range of OP1 expression levels.

## 2. Exemplary Mammalian Cells

Recombinant OP1 has been expressed in three different cell expression systems: COS cells for rapidly screening the functionality of the various expression vector constructs, CHO cells for the establishment of stable cell lines, and BSC40-tsA58 cells as an alternative means of producing OP1 protein.

## A. COS CELLS

COS cells (simian kidney cells) are used for rapid screening of vector constructs and for immediate, small scale production of OP1 protein. COS cells are well known in the art and are available commercially. The particular cell line described herein may be obtained through the American Type Culture Collection (ATCC #COS-1, CRL-1650).

OP1 expression levels from different vectors, analyzed by northern and western blot assays, are compared in Table I below:

TABLE 1

ANALYSIS OF OP1 EXPRESSION IN COS CELLS

<u>Vector</u>	<u>mRNA</u>	<u>OP1 Production</u>
pH717	+++	++
pH731	+	+
pH752	+++	++++
pH754	+++	++++

pH754-transfected COS cells appear to produce the highest yield of OP1 to date. However, because transfected COS cells do not divide and die several days post-transfection, large amounts of plasmid DNA are required for each scaled up transformation.

Large scale preparations of OP1 from transfected COS cells may be produced using conventional roller bottle technology. Briefly, 14 X



$10^6$  cells are used to seed each bottle. After 24 hrs of growth, the cells are transfected with 10  $\mu$ g of vector DNA (e.g., pH717) per  $10^6$  cells, using the DEAE-dextran method. Cells are then conditioned in serum-free media for 120 hr before harvesting the media for protein analysis. Following this protocol, OP1 yield is approximately 2-6 ng/ml.

#### B. CHO Cells

CHO cells (chinese hamster ovary cells) may be used for long term OP1 production. CHO cell lines are well characterized for the small and large scale production of foreign genes and are available commercially. The particular cell line described herein is CHO-DXB11, (Laurence Chasin, Columbia University, NY). Table II, below, shows exemplary OP1 yields obtained with a variety of expression vectors.

TABLE II

<u>CHO Cells</u>	<u>Plasmid</u>	<u>Selection Marker</u>	<u>OP1 Production ng/ml</u>
	pH717	NEO	2-5
*	pH752/pH754	DHFR	100-150

\*Cells are adapted to grow in  
0.1  $\mu$ M methotrexate

CHO cells may be transfected by conventional calcium phosphate technique. CHO cells preferably are transfected with pH754 or pH752 and are

conditioned in media containing serum proteins, as this appears to enhance OP1 yields. Useful media include media containing 0.1-0.5% dialyzed fetal calf serum (FCS).

### C. BSC CELLS

The BSC40-tsA58 cell line ("BSC cells") is a temperature-sensitive strain of simian kidney cells (1988, Biotechnology 6: 1192-1196) which overcomes some of the problems associated with COS cells. These BSC cells have the advantage of being able to amplify gene sequences rapidly on a large scale with temperature downshift, without requiring the addition of exogenous, potentially toxic drugs. In addition, the cells may be recycled. That is, after induction and stimulation of OP1 expression, the cells may be transferred to new growth medium, grown to confluence at 39.5°C and induced a second time by downshifting the temperature to 33°C. BSC cells may be used to establish stable cell lines rapidly for protein production.

Transfected BSC cells may be induced by shifting the temperature down to 33°C, in media containing 10% FCS, and harvesting the conditioned media after 96 hrs of incubation. Comparable amounts of OP1 RNA and protein are obtained, as compared with CHO cells (e.g., 100-150 ng OP1/ml conditioned media from BSC clones transfected with pH717).

### 3. Evaluation of OP1 transfected cells

Expression levels of transfected OP1 sequences can be measured in the different systems by analyzing mRNA levels (Northern blots), using total cellular RNA and conventional hybridization methodology. Generally, about  $1 \times 10^6$  cells are needed for mRNA analysis. Data between individual cell lines can be compared if the total number of cells and the total amount of mRNA is normalized, using rRNA as an internal standard. Ribosomal RNA is visualized in the agarose gel by ethidium bromide stain prior to transfer of the RNA to nitrocellulose sheets for hybridization. Ribosomal RNA also provides an indicator of the integrity of the RNA preparation.

OP1 protein levels also may be measured by Western blots (immunoblots) using rabbit antisera against human OP1. Figure 4 is an immunoblot showing OP1 production in: COS cells - (A) pH717, (B) pH731; CHO cells - (C) pH754, (D) pH752; and BSC cells - (E) pH717 and (F) pH24.

Southern blots may be used to assess the state of integrated OP1 sequences and the extent of their copy number amplification. The copy number of excised plasmids in temperature-shifted BSC cells also can be determined using Southern blot analysis.

## II. PROTEIN PURIFICATION

The purification scheme developed to purify the recombinant osteogenic proteins of this invention is rapid and highly effective. The protocol involves

three chromatographic steps (S-Sepharose, phenyl-Sepharose and C-18 HPLC), and produces OP1 of about 90% purity.

For a typical 2 L preparation of transfected BSC cells conditioned in 0.5% FCS, the total protein is 700 mg. The amount of OP1 in the media, estimated by western blot, is about 80  $\mu$ g. OP1 media is diluted to 6M urea, 0.05M NaCl, 13mM HEPES, pH 7.0 and loaded onto an S-Sepharose column, which has attached sulfite groups and acts as a strong cation exchanger. OP1 binds to the column in low salt, and serum proteins are removed. The column is subsequently developed with two step salt elutions. The first elution (0.1M NaCl) removes contaminants and approximately 10% of the bound OP1. The remaining 90% of OP1 then is eluted in 6M urea, 0.3M NaCl, 20mM HEPES, pH 7.0.

Ammonium sulfate is added to the 0.3M NaCl fraction to obtain final solution conditions of 6M urea, 1M  $(\text{NH}_4)_2\text{SO}_4$ , 0.3M NaCl, 20mM HEPES, pH 7.0. The sample then is loaded onto a phenyl-Sepharose column (hydrophobic interaction chromatography). OP1 binds phenyl-Sepharose in the presence of high concentrations of a weak chaotropic salt (e.g., 1M  $(\text{NH}_4)_2\text{SO}_4$ ). Once OP1 is bound, the column is developed with two step elutions using decreasing concentrations of ammonium sulfate. The first elution (containing 0.6M  $(\text{NH}_4)_2\text{SO}_4$ ) primarily removes contaminants. The bound OP1 then is eluted with a 6M urea, 0.3M NaCl, 20mM HEPES, pH 7.0 buffer containing no ammonium sulfate.

The OPl eluted from the phenyl-Sepharose column is dialyzed against water, followed by 30% acetonitrile (0.1% TFA), and then applied to a C-18 reverse phase HPLC column. Figures 5A, B, and C are (1) chromatograms and (2) coomassie-stained SDS-PAGE gels of fractions after reduction with dithiothreitol (DTT) eluting from the (A) S-Sepharose, (B) phenyl-Sepharose, and (C) C-18 columns. Gel separation of oxidized and reduced OPl samples show that the reduced subunit has an apparent molecular weight of about 18 kD, and the dimer has an apparent molecular weight of about 36 kD, as illustrated in Figure 6. The subunit size appears to be identical to that purified from COS cells, as well as that of the naturally-sourced bOP. The current protocol yields about 30 ug of OPl for 2 L of conditioned media, a recovery of about 25%, as estimated by gel scanning.

An alternative chromatography protocol is to perform the S-Sepharose chromatography in the absence of 6 M urea. The bound proteins then are eluted with salt step elutions (e.g., 100-400 mM NaCl). Most of the OPl is eluted with about 300 mM NaCl. Additional OPl then can be eluted with 300 mM NaCl in the presence of 6M urea. The 6M urea elution also may be used in place of the non-urea elution to achieve maximum recovery in one step.

OPl also will bind hydroxyapatite efficiently, but only in the absence of 6 M urea and at low phosphate concentrations (less than 5 mM phosphate). Bound OPl can be removed from the column with a step elution of 1 mM to 0.5M phosphate (in 0.5

M NaCl, 50 mM Tris, pH 7.0). OPl elutes at about 250 mM phosphate. Additionally, urea (6M) may be added during the elution step.

Other related chromatography methods also may be useful in purifying OPl from eukaryotic cell culture systems. For example, heparin-Sepharose may be used in combination with the S-Sepharose column. Alternatively,  $\text{Cu}^{2+}$ -immobilized metal-ion affinity chromatography (IMAC) will bind OPl in a phosphate buffer (pH7.0) containing 6M urea.

### III. MATRIX PREPARATION

Practice of the invention requires the availability of bone, preferably mammalian bone, e.g., bovine. The bone is cleaned, demarrowed, delipidated, demineralized, reduced to particles of an appropriate size, extracted to remove soluble proteins, sterilized, and otherwise treated as disclosed herein to produce an implantable material useful in a variety of clinical settings.

Matrices of various shapes fabricated from the material of the invention may be implanted surgically for various purposes. Chief among these is to serve as a matrix for bone formation in various orthopedic, periodontal, and reconstructive procedures, as a sustained release carrier, or as a collagenous coating for implants. The matrix may be shaped as desired in anticipation of surgery or shaped by the physician or technician during surgery. Thus, the material may be used for topical, subcutaneous, intraperitoneal, or intramuscular

implants; it may be shaped to span a nonunion fracture or to fill a bone defect. In bone formation or conduction procedures, the material is slowly absorbed by the body and is replaced by bone in the shape of or very nearly the shape of the implant.

Various growth factors, hormones, enzymes, therapeutic compositions, antibiotics, and other body treating agents also may be sorbed onto the carrier material and will be released over time when implanted as the matrix material is slowly absorbed. Thus, various known growth factors such as EGF, PDGF, IGF, FGF, TGF alpha, and TGF beta may be released in vivo. The material can be used to release chemotherapeutic agents, insulin, enzymes, or enzyme inhibitors.

Details of how to make and how to use the materials of the invention are disclosed below.

1. Preparation of Demineralized Bone

Demineralized bovine bone matrix is prepared by previously published procedures (Sampath and Reddi (1983) Proc. Natl. Acad. Sci. USA 80:6591-6595). Bovine diaphyseal bones (age 1-10 days) are obtained from a local slaughterhouse and used fresh. The bones are stripped of muscle and fat, cleaned of periosteum, demarrowed by pressure with cold water, dipped in cold absolute ethanol, and stored at -20°C. They are then dried and fragmented by crushing and pulverized in a large mill. Care is

taken to prevent heating by using liquid nitrogen. The pulverized bone is milled to a particle size in the range of 70-850  $\mu\text{m}$ , preferably 150  $\mu\text{m}$ -420  $\mu\text{m}$ , and is defatted by two washes of approximately two hours duration with three volumes of chloroform and methanol (3:1). The particulate bone is then washed with one volume of absolute ethanol and dried over one volume of anhydrous ether yielding defatted bone powder. The defatted bone powder is then demineralized by four successive treatments with 10 volumes of 0.5 N HCl at 4°C for 40 min. Finally, neutralizing washes are done on the demineralized bone powder with a large volume of water.

## 2. Guanidine Extraction

Demineralized bone matrix thus prepared is extracted with 5 volumes of 4 M guanidine-HCl, 50mM Tris-HCl, pH 7.0 for 16 hr. at 4°C. The suspension is filtered. The insoluble material is collected and used to fabricate the matrix. The material is mostly collagenous in nature. It is devoid of osteogenic or condrogenic activity.

## 3. Matrix Treatments

The major component of all bone matrices is Type-I collagen. In addition to collagen, demineralized bone extracted as disclosed above includes non-collagenous proteins which may account for 5% of its mass. In a xenogenic matrix, these noncollagenous components may present themselves as potent antigens, and may constitute immunogenic and/or inhibitory components. These components also



may inhibit osteogenesis in allogenic implants by interfering with the developmental cascade of bone differentiation. It has been discovered that treatment of the matrix particles with a collagen fibril-modifying agent extracts potentially unwanted components from the matrix, and alters the surface structure of the matrix material.

The currently most preferred fibril modifying agent is a heated aqueous medium, most preferably water. Various amounts of delipidated, demineralized guanidine-extracted bone collagen is heated in water (1 g/30 ml) under constant stirring in a glass flask, water jacked, and maintained at a given temperature for 1 hour. In some instances the water may be replaced with 0.1M acetic acid to help "swell" the collagen before heating. The temperature employed is held constant at room temperature, and about 37°C, 45°C, 55°, 65°, 75°. After the heat treatment, the matrix is filtered and lyophilized and used for implant.

The effects of hot water treatment on morphology of the matrix material is apparent from a comparison of the photomicrographs in Figure 6 with those of Figure 1. Figure 6 illustrates the morphology of the successfully altered collagen surface treated at (a) 37°C, (b) 45°C, (c) 55°C and (d) 65°C. The photomicrographs of Figure 1 describe the morphology of untreated rat and bovine bone matrix (A and B, respectively). As is evident from the micrographs, the hot water treatment increases the degree of micropitting on the particle surface at least about 10-fold, as well as also substantially

increasing particle's porosity (compare Figure 1B and 5C, 5D). This alteration of the matrix particle's morphology substantially increases the particle surface area. Careful measurement of the pore and micropit sizes reveals that hot aqueous medium treatment of the matrix particles yields particle pore and micropit diameters within the range of 1 $\mu$ m to 100 $\mu$ m.

Characterization of the extract produced by the hot water treatment reveals that the treatment also may be removing component(s) whose association with the matrix may interfere with new bone formation in vivo. Figure 8 is a 214 nm absorbance tracing of the extract isolated from hot water treated bovine matrix, and indicates the effect of each peak (or fraction) on in vivo bone formation.

The extract from a large scale preparative run (100 g bovine matrix, hot water-treated) was collected, acidified with 0.1% TFA, and run on a C-18 HPLC column, using a Millipore Delta Prep Cartridge. Fractions were collected at 50 mL intervals at a flow rate of 25 ml/min. and pooled appropriately to isolate the individual peaks in the tracing. Each of these fractions then was implanted with recombinant OP1 and an appropriate rat matrix carrier (see *infra*), and its effect on bone formation activity measured. Fraction 12 alone appears to inhibit bone formation in allogenic implants. The inhibitory activity appears to be dose dependent. It is possible that the removal of the inhibitory component(s) present in this peak may be necessary to support osteogenic activity in xenogenic implants.

Figure 9 describes the influence of complete solvent extract from hot water-treated matrix on osteogenic activity as measured in 12-day implants, and determined by alkaline phosphatase activity and calcium content. Rat carrier matrix and OP1 implanted without any extract is used as a positive control. The solvent extract obtained from 100 grams of hot water-treated bovine matrix was evaporated and taken up in 6 M of 50% acetonitrile/0.1% TFA. 100-300  $\mu$ l aliquots then were combined with known amounts of recombinant OP1, and 25 mg of rat matrix carrier, and assayed (see infra). The results clearly show the extract inhibits new bone formation in a dose dependent manner.

After contact with the fibril-modifying agent, the treated matrix is washed to remove any extracted components, following a form of the procedure set forth below:

1. Suspend in TBS (Tris-buffered saline) 1g/200 ml and stir at 4°C for 2 hrs; or in 6 M urea, 50 mM Tris-HCl, 500 mM NaCl, pH 7.0 (UTBS) or water and stir at room temperature (RT) for 30 minutes (sufficient time to neutralize the pH);
2. Centrifuge and repeat wash step; and
3. Centrifuge; discard supernatant; water wash residue; and then lyophilize.

Other useful fibril-modifying agents include acids such as trifluoroacetic acid and hydrogen

fluoride, and organic solvents such as dichloromethane, acetonitrile, isopropanol, and chloroform, as well as combinations of these agents. Matrix treatments using these other fibril-modifying agents, as well as a detailed physical analysis of the effect these fibril-modifying agents have on demineralized, guanidine-extracted bone collagen particles is disclosed in copending U.S. Patent Application No. 422,613, filed 10/17/89, the disclosure of which is hereby incorporated by reference.

The collagen matrix materials preferably take the form of a fine powder, insoluble in water, comprising nonadherent particles. It may be used simply by packing into the volume where new bone growth or sustained release is desired, held in place by surrounding tissue. Alternatively, the powder may be encapsulated in, e.g., a gelatin or polylactic acid coating, which is adsorbed readily by the body. The powder may be shaped to a volume of given dimensions and held in that shape by interadhering the particles using, for example, soluble, species biocompatible collagen. The material may also be produced in sheet, rod, bead, or other macroscopic shapes.

#### IV. FABRICATION OF OSTEOGENIC DEVICE

The recombinant protein as set forth above, and other constructs, can be combined and dispersed in a suitable matrix preparation using any of the methods described below:

1. Ethanol Precipitation

Matrix is added to osteogenic protein dissolved in guanidine-HCl. Samples are vortexed and incubated at a low temperature. Samples are then further vortexed. Cold absolute ethanol is added to the mixture which is then stirred and incubated. After centrifugation (microfuge, high speed) the supernatant is discarded. The matrix is washed with cold concentrated ethanol in water and then lyophilized.

2. Acetonitrile Trifluoroacetic  
Acid Lyophilization

In this procedure, osteogenic protein in an acetonitrile trifluoroacetic acid (ACN/TFA) solution was added to the carrier material. Samples were vigorously vortexed many times and then lyophilized. Osteogenic protein was added in varying concentrations, and at several levels of purity. This method is currently preferred.

3. Urea Lyophilization

For those osteogenic proteins that are prepared in urea buffer, the protein is mixed with the matrix material, vortexed many times, and then lyophilized. The lyophilized material may be used "as is" for implants.

#### 4. Buffered Saline Lyophilization

OP preparations in physiological saline may also be vortexed with the matrix and lyophilized to produce osteogenically active material.

These procedures also can be used to adsorb other active therapeutic drugs, hormones, and various bioactive species for sustained release purposes.

#### V. BIOASSAY

The functioning of the various matrices can be evaluated with an in vivo rat bioassay. Studies in rats show the osteogenic effect in an appropriate matrix to be dependent on the dose of osteogenic protein dispersed in the matrix. No activity is observed if the matrix is implanted alone. Demineralized, guanidine extracted xenogenic bone matrix materials of the type described in the literature are ineffective as a carrier, fail to induce bone, and produce an inflammatory and immunological response when implanted unless treated as disclosed above. Many of the allogenic matrix materials also are ineffective as carriers. The following sets forth various procedures for preparing osteogenic devices from control and matrix materials prepared as set forth above, and for evaluating their osteogenic utility.

##### Implantation

The bioassay for bone induction as described by Sampath and Reddi (Proc. Natl. Acad. Sci. USA (1983) 80: 6591-6595), herein incorporated by reference, may be used to monitor endochondral bone

differentiation activity. This assay consists of implanting the bovine test samples xenogenically in subcutaneous sites in recipient rats under ether anesthesia. Male Long-Evans rats, aged 28-32 days, were used. A vertical incision (1 cm) is made under sterile conditions in the skin over the thoracic region, and a pocket is prepared by blunt dissection. Approximately 25 mg of the test sample is implanted deep into the pocket and the incision is closed with a metallic skin clip. The day of implantation is designated as day of the experiment. Implants were removed on day 12. The heterotopic site allows for the study of bone induction without the possible ambiguities resulting from the use of orthotopic sites.

#### Cellular Events

Successful implants exhibit a controlled progression through the stages of matrix induced endochondral bone development including: (1) transient infiltration by polymorphonuclear leukocytes on day one; (2) mesenchymal cell migration and proliferation on days two and three; (3) chondrocyte appearance on days five and six; (4) cartilage matrix formation on day seven; (5) cartilage calcification on day eight; (6) vascular invasion, appearance of osteoblasts, and formation of new bone on days nine and ten; (7) appearance of osteoblastic and bone remodeling and dissolution of the implanted matrix on days twelve to eighteen; and (8) hematopoietic bone marrow differentiation in the ossicle on day twenty-one. The results show that the shape of the new bone conforms to the shape of the implanted matrix.

### Histological Evaluation

Histological sectioning and staining is preferred to determine the extent of osteogenesis in the implants. Implants are fixed in Bouins Solution, embedded in paraffin, and cut into 6-8  $\mu$ m sections. Staining with toluidine blue or hemotoxylin/eosin demonstrates clearly the ultimate development of endochondral bone. Twelve day implants are usually sufficient to determine whether the implants contain newly induced bone.

### Biological Markers

Alkaline phosphatase activity may be used as a marker for osteogenesis. The enzyme activity may be determined spectrophotometrically after homogenization of the implant. The activity peaks at 9-10 days in vivo and thereafter slowly declines. Implants showing no bone development by histology have little or no alkaline phosphatase activity under these assay conditions. The assay is useful for quantitation and obtaining an estimate of bone formation quickly after the implants are removed from the rat. Alternatively, the amount of bone formation can be determined by measuring the calcium content of the implant.

### Results

OP1 from different cell sources and purified to different extents (1-5% pure to 30-90% pure) were tested for osteogenic activity in vivo as set forth



above using matrices of approximately 25 mg. Table III below shows the histology score for OP1 expressed in all three cell types.

TABLE III

<u>Mammalian Cells</u>	<u>OP1 Subunit</u>	<u>Protein Concentration† (ng)</u>	<u>Histology Score (%)</u>
BSC40-tsA58	18kDa*	32.5	50
		65.0	40
		130.0	80
		260.0	100
	16 kDa <sup>+</sup>	12.5	20
		25.0	50
		50.0	80
		100.0	100
		200.0	100
CHO	16-20 kDa <sup>S</sup>	50.0	90
		100.0	90
		200.0	100
COS	18 kDa <sup>S</sup>	25.0	10
		50.0	30
		100.0	90
		200.0	90

10-30%: moderate bone formation

30-80%: extensive bone formation

above 80%: showed sign of hemopoietic bone  
marrow recruitment.

\* 70-90% pure

+ 30-40% pure

<sup>S</sup> less than 5% pure

† estimated by immunoblots or gel scanning

The histology scores detailed in Table III show that OP1 is active regardless of cell source,

and that the activity mimics that of native bovine OP. The bone-inducing activity is highly reproducible and dose dependent. Further evidence of the bone-forming activity of recombinant OP1 is provided in the photomicrographs of Figures 10 and 11.

Figure 10A-F are photomicrographs recording the histology of allogenic implants using recombinant OP1 expressed from COS, BSC, and COS cells. The micrographs (magnified 220X), provide graphic evidence of the full developmental cascade induced by the osteogenic proteins of this invention, confirming that recombinantly produced OP1 alone is sufficient to induce endochondral bone formation, when implanted in association with a matrix. As evidenced in Figure 10A, allogenic implants that do not contain OP1 show no new bone formation at 12 days' post implant. Only the implanted bone matrix (m) and surrounding mesenchyme are seen. Conversely, implants containing OP1 already show evidence of extensive chondrogenesis by 7 days post implant (Fig. 10B, 500 ng BSC-produced protein, 30% pure). Here, newly formed cartilage cells, chondroblasts (Cb) and chondrocytes (Cy) are in close contact with the matrix (m). By 9 days post implant endochondral bone differentiation, cartilage calcification, hypertrophy of chondrocytes, vascular invasion, and the onset of new bone formation are all evident (Fig. 10C, 220 ng COS-produced protein, approx. 5% pure). Invading capillaries (c) and the appearance of basophilic osteoblasts (indicated by arrows) near the vascular endothelium are particularly evident. By 12 days post implant extensive bone formation and remodeling has occurred (Fig. 10D (220X), and 10E (400X), CHO-produced

protein, approx. 60% pure). The newly formed bone laid down by osteoblasts is being remodeled by multinucleated osteoclasts (Oc), and the implanted matrix is being resorbed and replaced by remodeled bone. Bone marrow recruitment in the newly formed ossicles is also evident. Finally, hematopoietic bone marrow differentiation within the ossicles can be seen by 22 days' post implant (Fig. 10F, 500 ng BSC-produced protein, 30% pure). By this time most of the implanted matrix (m) has been resorbed and is occupied by newly-formed bone containing ossicles filled with bone marrow elements including erythrocytic and granulocytic series and megakaryocytes. Similar histological observations have been made for implants incorporating greater than 90% pure OP1 preparations.

Figure 11 is a photomicrograph showing the histology at 12 days post implant for a xenogenic implant using hot water-treated bovine matrix and OP1 (BSC-produced). The recruitment of hematopoietic bone marrow elements is evident in the photomicrograph, showing that the bone forming activity of xenogenic implants with OP1 parallels that of allogenic implants (compare Figure 11 with Figures 10D and 10E).

The cellular events exhibited by the OP1 matrix implants and evidenced in Figures 10 and 11 truly mimics the endochondral bone differentiation that occurs during the foetal development. Although endochondral bone differentiation has been the predominant route, there is also evidence for intra-membraneous bone formation at the outer surface of the implant.

Figures 12 and 13 describe the dose dependence of osteogenic activity for 12-day implants, as determined by specific activity of alkaline phosphatase and calcium content of allogenic implants (Figure 12) and xenogenic implants of this invention (Figure 13). In all cases, OP1 protein concentration (quantitated by immuno blot staining or by gel scanning), is represented in nanograms. In each case, bone inducing activity is specific to OP1 in a dose dependent manner in all cells.

The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The present embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Oppermann, Hermann  
Kuberasampath, Thangavel  
Rueger, David C.  
Ozkaynak, Engin  
Pang, Roy H.L.
- (ii) TITLE OF INVENTION: Osteogenic Devices
- (iii) NUMBER OF SEQUENCE: 7
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Lahive & Cockfield
  - (B) STREET: 60 State Street
  - (C) CITY: Boston
  - (D) STATE: Massachusetts
  - (E) COUNTRY: U.S.A.
  - (F) ZIP: 02109
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Diskette, 3.5 inch,  
720kb storage
  - (B) COMPUTER: IBM XT
  - (C) OPERATING SYSTEM: DOS 3.30
  - (D) SOFTWARE: Word Perfect 5.0
- (vi) CURRENT APPLICATION DATA:
  - (B) FILING DATE: 20-Aug-90
- (vii) PRIOR APPLICATION DATA:
  - (A) APPLICATION NUMBER: US 422,699
  - (B) FILING DATE: 17-Oct-89
  - (C) APPLICATION NUMBER: US 483,913
  - (D) FILING DATE: 22-Feb-89

## (2) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 139 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Ser	Thr	Gly	Ser	Lys	Gln	Arg	Ser	Gln
1				5				
Asn	Arg	Ser	Lys	Thr	Pro	Lys	Asn	Gln
10					15			
Glu	Ala	Leu	Arg	Met	Ala	Asn	Val	Ala
	20					25		
Glu	Asn	Ser	Ser	Ser	Asp	Gln	Arg	Gln
		30					35	
Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr	Val
			40					45
Ser	Phe	Arg	Asp	Leu	Gly	Trp	Gln	Asp
				50				
Trp	Ile	Ile	Ala	Pro	Glu	Gly	Tyr	Ala
55					60			
Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala
	65					70		
Phe	Pro	Leu	Asn	Ser	Tyr	Met	Asn	Ala
		75					80	
Thr	Asn	His	Ala	Ile	Val	Gln	Thr	Leu
			85					90
Val	His	Phe	Ile	Asn	Pro	Glu	Thr	Val
				95				
Pro	Lys	Pro	Cys	Cys	Ala	Pro	Thr	Gln
100					105			
Leu	Asn	Ala	Ile	Ser	Val	Leu	Tyr	Phe
	110					115		

-61-

Asp	Asp	Ser	Ser	Asn	Val	Ile	Leu	Lys
		120					125	
Lys	Tyr	Arg	Asn	Met	Val	Val	Arg	Ala
			130					135
Cys	Gly	Cys	His.					

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 132 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

							Ser	Gln
							1	
Asn	Arg	Ser	Lys	Thr	Pro	Lys	Asn	Gln
		5					10	
Glu	Ala	Leu	Arg	Met	Ala	Asn	Val	Ala
			15					20
Glu	Asn	Ser	Ser	Ser	Asp	Gln	Arg	Gln
				25				
Ala	Cys	Lys	Lys	His	Glu	Leu	Tyr	Val
30					35			
Ser	Phe	Arg	Asp	Leu	Gly	Trp	Gln	Asp
	40					45		
Trp	Ile	Ile	Ala	Pro	Glu	Gly	Tyr	Ala
		50					55	
Ala	Tyr	Tyr	Cys	Glu	Gly	Glu	Cys	Ala
			60					65
Phe	Pro	Leu	Asn	Ser	Tyr	Met	Asn	Ala
				70				

-62-

Thr 75	Asn	His	Ala	Ile	Val 80	Gln	Thr	Leu
Val 85	His	Phe	Ile	Asn	Pro	Glu 90	Thr	Val
Pro	Lys	Pro 95	Cys	Cys	Ala	Pro	Thr 100	Gln
Leu	Asn	Ala	Ile 105	Ser	Val	Leu	Tyr	Phe 110
Asp	Asp	Ser	Ser	Asn 115	Val	Ile	Leu	Lys
Lys 120	Tyr	Arg	Asn	Met	Val 125	Val	Arg	Ala
Cys 130	Gly	Cys	His.					

## (2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 119 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Leu 1	Arg	Met	Ala	Asn 5	Val	Ala	Glu	Asn
Ser 10	Ser	Ser	Asp	Gln	Arg 15	Gln	Ala	Cys
Lys 20	Lys	His	Glu	Leu	Tyr	Val 25	Ser	Phe
Arg	Asp	Leu	Gly	Trp	Gln	Asp	Trp 35	Ile
Ile	Ala	Pro	Glu 40	Gly	Tyr	Ala	Ala	Tyr 45



-63-

Tyr	Cys	Glu	Gly	Glu	Cys	Ala	Phe	Pro
				50				
Leu	Asn	Ser	Tyr	Met	Asn	Ala	Thr	Asn
55					60			
His	Ala	Ile	Val	Gln	Thr	Leu	Val	His
	65					70		
Phe	Ile	Asn	Pro	Glu	Thr	Val	Pro	Lys
		75					80	
Pro	Cys	Cys	Ala	Pro	Thr	Gln	Leu	Asn
			85					90
Ala	Ile	Ser	Val	Leu	Tyr	Phe	Asp	Asp
				95				
Ser	Ser	Asn	Val	Ile	Leu	Lys	Lys	Tyr
100					105			
Arg	Asn	Met	Val	Val	Arg	Ala	Cys	Gly
	110					115		
Cys	His	.						

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 117 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

		Met	Ala	Asn	Val	Ala	Glu	Asn
		1				5		
Ser	Ser	Ser	Asp	Gln	Arg	Gln	Ala	Cys
		10					15	
Lys	Lys	His	Glu	Leu	Tyr	Val	Ser	Phe
			20					25
Arg	Asp	Leu	Gly	Trp	Gln	Asp	Trp	Ile
				30				

-64-

Ile	Ala	Pro	Glu	Gly	Tyr	Ala	Ala	Tyr
35					40			
Tyr	Cys	Glu	Gly	Glu	Cys	Ala	Phe	Pro
	45					50		
Leu	Asn	Ser	Tyr	Met	Asn	Ala	Thr	Asn
		55					60	
His	Ala	Ile	Val	Gln	Thr	Leu	Val	His
			65					70
Phe	Ile	Asn	Pro	Glu	Thr	Val	Pro	Lys
				75				
Pro	Cys	Cys	Ala	Pro	Thr	Gln	Leu	Asn
80					85			
Ala	Ile	Ser	Val	Leu	Tyr	Phe	Asp	Asp
	90					95		
Ser	Ser	Asn	Val	Ile	Leu	Lys	Lys	Tyr
		100					105	
Arg	Asn	Met	Val	Val	Arg	Ala	Cys	Gly
			110					115
Cys	His	.						

## (2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 116 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

			Ala	Asn	Val	Ala	Glu	Asn
			1				5	
Ser	Ser	Ser	Asp	Gln	Arg	Gln	Ala	Cys
			10					15
Lys	Lys	His	Glu	Leu	Tyr	Val	Ser	Phe
				20				

-65-

Arg 25	Asp	Leu	Gly	Trp	Gln 30	Asp	Trp	Ile
Ile	Ala 35	Pro	Glu	Gly	Tyr	Ala 40	Ala	Tyr
Tyr	Cys	Glu 45	Gly	Glu	Cys	Ala	Phe 50	Pro
Leu	Asn	Ser	Tyr 55	Met	Asn	Ala	Thr	Asn 60
His	Ala	Ile	Val	Gln 65	Thr	Leu	Val	His
Phe 70	Ile	Asn	Pro	Glu	Thr 75	Val	Pro	Lys
Pro	Cys 80	Cys	Ala	Pro	Thr	Gln 85	Leu	Asn
Ala	Ile	Ser 90	Val	Leu	Tyr	Phe	Asp 95	Asp
Ser	Ser	Asn	Val 100	Ile	Leu	Lys	Lys	Tyr 105
Arg	Asn	Met	Val	Val 110	Arg	Ala	Cys	Gly
Cys 115	His	.						

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 114 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Val	Ala	Glu	Asn	Ser	Ser	Ser	Asp	Gln
1				5				
Arg	Gln	Ala	Cys	Lys	Lys	His	Glu	Leu
10					15			
Tyr	Val	Ser	Phe	Arg	Asp	Leu	Gly	Trp
	20					25		
Gln	Asp	Trp	Ile	Ile	Ala	Pro	Glu	Gly
		30					35	
Tyr	Ala	Ala	Tyr	Tyr	Cys	Glu	Gly	Glu
			40					45
Cys	Ala	Phe	Pro	Leu	Asn	Ser	Tyr	Met
				50				
Asn	Ala	Thr	Asn	His	Ala	Ile	Val	Gln
55					60			
Thr	Leu	Val	His	Phe	Ile	Asn	Pro	Glu
	65					70		
Thr	Val	Pro	Lys	Pro	Cys	Cys	Ala	Pro
		75					80	
Thr	Gln	Leu	Asn	Ala	Ile	Ser	Val	Leu
			85					90
Tyr	Phe	Asp	Asp	Ser	Ser	Asn	Val	Ile
				95				
Leu	Lys	Lys	Tyr	Arg	Asn	Met	Val	Val
100					105			
Arg	Ala	Cys	Gly	Cys	His	.		
	110							

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1822 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

-67-

- (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: no
- (iv) ANTI-SENSE: no
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: Bovinae
  - (F) TISSUE TYPE: bone
- (vii) IMMEDIATE SOURCE:
  - (A) LIBRARY: human placenta
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

```

GGTGCGGGCC CGGAGCCCGG AGCCCGGGTA GCGCGTAGAG      40

CCGGCGCG ATG CAC GTG CGC TCA CTG CGA GCT GCG      75
    Met His Val Arg Ser Leu Arg Ala Ala
        1                      5

GCG CCG CAC AGC TTC GTG GCG CTC TGG GCA CCC      108
Ala Pro His Ser Phe Val Ala Leu Trp Ala Pro
    10                      15                      20

CTG TTC CTG CTG CGC TCC GCC CTG GCC GAC TTC      141
Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe
        25                      30

AGC CTG GAC AAC GAG GTG CAC TCG AGC TTC ATC      174
Ser Leu Asp Asn Glu Val His Ser Ser Phe Ile
        35                      40

CAC CGG CGC CTC CGC AGC CAG GAG CGG CGG GAG      207
His Arg Arg Leu Arg Ser Gln Glu Arg Arg Glu
        45                      50

ATG CAG CGC GAG ATC CTC TCC ATT TTG GGC TTG      240
Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu
        55                      60

CCC CAC CGC CCG CGC CCG CAC CTC CAG GGC AAG      273
Pro His Arg Pro Arg Pro His Leu Gln Gly Lys
        65                      70                      75

```

CAC AAC TCG GCA CCC ATG TTC ATG CTG GAC CTG	306
His Asn Ser Ala Pro Met Phe Met Leu Asp Leu	
80 85	
TAC AAC GCC ATG GCG GTG GAG GAG GGC GGC GGG	339
Tyr Asn Ala Met Ala Val Glu Glu Gly Gly Gly	
90 95	
CCC GGC GGC CAG GGC TTC TCC TAC CCC TAC AAG	372
Pro Gly Gly Gln Gly Phe Ser Tyr Pro Tyr Lys	
100 105	
GCC GTC TTC AGT ACC CAG GGC CCC CCT CTG GCC	405
Ala Val Phe Ser Thr Gln Gly Pro Pro Leu Ala	
110 115	
AGC CTG CAA GAT AGC CAT TTC CTC ACC GAC GCC	438
Ser Leu Gln Asp Ser His Phe Leu Thr Asp Ala	
120 125 130	
GAC ATG GTC ATG AGC TTC GTC AAC CTC GTG GAA	471
Asp Met Val Met Ser Phe Val Asn Leu Val Glu	
135 140	
CAT GAC AAG GAA TTC TTC CAC CCA CGC TAC CAC	504
His Asp Lys Glu Phe Phe His Pro Arg Tyr His	
145 150	
CAT CGA GAG TTC CGG TTT GAT CTT TCC AAG ATC	537
His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile	
155 160	
CCA GAA GGG GAA GCT GTC ACG GCA GCC GAA TTC	570
Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe	
165 170	
CGG ATC TAC AAG GAC TAC ATC CGG GAA CGC TTC	603
Arg Ile Tyr Lys Asp Tyr Ile Arg Glu Arg Phe	
175 180 185	
GAC AAT GAG ACG TTC CGG ATC AGC GTT TAT CAG	636
Asp Asn Glu Thr Phe Arg Ile Ser Val Tyr Gln	
190 195	
GTG CTC CAG GAG CAC TTG GGC AGG GAA TCG GAT	669

Val	Leu	Gln	Glu	His	Leu	Gly	Arg	Glu	Ser	Asp	
			200					205			
CTC	TTC	CTG	CTC	GAC	AGC	CGT	ACC	CTC	TGG	GCC	702
Leu	Phe	Leu	Leu	Asp	Ser	Arg	Thr	Leu	Trp	Ala	
		210					215				
TCG	GAG	GAG	GGC	TGG	CTG	GTG	TTT	GAC	ATC	ACA	735
Ser	Glu	Glu	Gly	Trp	Leu	Val	Phe	Asp	Ile	Thr	
	220					225					
GCC	ACC	AGC	AAC	CAC	TGG	GTG	GTC	AAT	CCG	CGG	768
Ala	Thr	Ser	Asn	His	Trp	Val	Val	Asn	Pro	Arg	
230					235					240	
CAC	AAC	CTG	GGC	CTG	CAG	CTC	TCG	GTG	GAG	ACG	801
His	Asn	Leu	Gly	Leu	Gln	Leu	Ser	Val	Glu	Thr	
			245						250		
CTG	GAT	GGG	CAG	AGC	ATC	AAC	CCC	AAG	TTG	GCG	834
Leu	Asp	Gly	Gln	Ser	Ile	Asn	Pro	Lys	Leu	Ala	
		255						260			
GGC	CTG	ATT	GGG	CGG	CAC	GGG	CCC	CAG	AAC	AAG	867
Gly	Leu	Ile	Gly	Arg	His	Gly	Pro	Gln	Asn	Lys	
	265					270					
CAG	CCC	TTC	ATG	GTG	GCT	TTC	TTC	AAG	GCC	ACG	900
Gln	Pro	Phe	Met	Val	Ala	Phe	Phe	Lys	Ala	Thr	
	275					280					
GAG	GTC	CAC	TTC	CGC	AGC	ATC	CGG	TCC	ACG	GGG	933
Glu	Val	His	Phe	Arg	Ser	Ile	Arg	Ser	Thr	Gly	
285					290					295	
AGC	AAA	CAG	CGC	AGC	CAG	AAC	CGC	TCC	AAG	ACG	966
Ser	Lys	Gln	Arg	Ser	Gln	Asn	Arg	Ser	Lys	Thr	
			300						305		
CCC	AAG	AAC	CAG	GAA	GCC	CTG	CGG	ATG	GCC	AAC	999
Pro	Lys	Asn	Gln	Glu	Ala	Leu	Arg	Met	Ala	Asn	
		310						315			
GTG	GCA	GAG	AAC	AGC	AGC	AGC	GAC	CAG	AGG	CAG	1032

-70-

Val Ala Glu Asn Ser Ser Ser Asp Gln Arg Gln	
320	325
GCC TGT AAG AAG CAC GAG CTG TAT GTC AGC TTC	1065
Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe	
330	335
CGA GAC CTG GGC TGG CAG GAC TGG ATC ATC GCG	1098
Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala	
340	345 350
CCT GAA GGC TAC GCC GCC TAC TAC TGT GAG GGG	1131
Pro Glu Gly Tyr Ala Ala Tyr Tyr Cys Glu Gly	
	355 360
GAG TGT GCC TTC CCT CTG AAC TCC TAC ATG AAC	1164
Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn	
	365 370
GCC ACC AAC CAC GCC ATC GTG CAG ACG CTG GTC	1197
Ala Thr Asn His Ala Ile Val Gln Thr Leu Val	
	375 380
CAC TTC ATC AAC CCG GAA ACG GTG CCC AAG CCC	1230
His Phe Ile Asn Pro Glu Thr Val Pro Lys Pro	
	385 390
TGC TGT GCG CCC ACG CAG CTC AAT GCC ATC TCC	1263
Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile Ser	
	395 400 405
GTC CTC TAC TTC GAT GAC AGC TCC AAC GTC ATC	1296
Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile	
	410 415
CTG AAG AAA TAC AGA AAC ATG GTG GTC CGG GCC	1329
Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala	
	420 425
TGT GGC TGC CAC TAGCTCCTCC GAGAATTCAG	1361
Cys Gly Cys His	
	430
ACCCTTTGGG GCCAAGTTTT TCTGGATCCT CCATTGCTCG	1401



CCTTGGCCAG GAACCAGCAG ACCAACTGCC TTTTGTGAGA 1441  
CCTTCCCCTC CCTATCCCCA ACTTTAAAGG TGTGAGAGTA 1481  
TTAGGAAACA TGAGCAGCAT ATGGCTTTTG ATCAGTTTTT 1521  
CAGTGGCAGC ATCCAATGAA CAAGATCCTA CAAGCTGTGC 1561  
AGGCAAAACC TAGCAGGAAA AAAAAACAAC GCATAAAGAA 1601  
AAATGGCCGG GCCAGGTCAT TGGCTGGGAA GTCTCAGCCA 1641  
TGCACGGACT CGTTTCCAGA GGTAATTATG AGCGCCTACC 1681  
AGCCAGGCCA CCCAGCCGTG GGAGGAAGGG GCGGTGGCAA 1721  
GGGGTGGGCA CATTGGTGTC TGTGCGAAAG GAAAATTGAC 1761  
CCGGAAGTTC CTGTAATAAA TGTACAATA AAACGAATGA 1801  
ATGAAAAAAA AAAAAAAAAA A 1822

What is claimed is:

1. An osteogenic device for implantation in a mammal, the device comprising:
- a biocompatible, in vivo biodegradable matrix of mineral-free, delipidated Type I insoluble bone collagen particles, depleted in noncollagenous protein; and
  - a protein produced by the expression of recombinant DNA in a mammalian host cell, the protein comprising two oxidized subunits, the amino acid sequence of each subunit being sufficiently duplicative of the amino sequence (Seq. ID No.6):

OP1-16V

[illegible]

such that the dimeric species comprising said subunits has a conformation that is capable of inducing endochondral bone formation in a mammal when disposed within said matrix and implanted in said mammal.

2. An osteogenic protein expressed from recombinant DNA in a mammalian host cell and capable of inducing endochondral bone formation in a mammal when disposed within a matrix implanted in said mammal;

a protein produced by the expression of recombinant DNA in a mammalian host cell, the protein comprising two oxidized subunits, the amino acid sequence of each subunit being sufficiently duplicative of the amino sequence (Seq. ID No.6):

QP1-16V

[illegible]

such that the dimeric species comprising said subunits has a conformation that is capable of inducing endochondral bone formation in a mammal when disposed within said matrix and implanted in said mammal.

-74-

3. The invention of claim 1 or 2 wherein the amino acid sequence of each said subunit has at least 70% homology with the amino acid sequence (Seq. ID No.6):

OP1-16V

```

                                     30
                                     V A E N S
                                     40
S S D Q R Q A C K K H E L Y V
      50
S F R D L G W Q D W I I A P E
      70
G Y A A Y Y C E G E C A F P L
      80
N S Y M N A T N H A I V Q T L
      100
V H F I N P E T V P K P C C A
      110
P T Q L N A I S V L Y F D D S
      130
S N V I L K K Y R N M V V R A
C G C H.

```

4. The invention of claim 1 or 2 wherein the amino acid sequence of each said subunit has at least 80% homology with the amino acid sequence (Seq. ID No.6):

OP1-16V

```

                                     30
                                     V A E N S
                                     40
S S D Q R Q A C K K H E L Y V
      50
S F R D L G W Q D W I I A P E
      70
G Y A A Y Y C E G E C A F P L

```

-75-

```

      80
N  S  Y  M  N  A  T  N  H  A  I  V  Q  T  L
      100
V  H  F  I  N  P  E  T  V  P  K  P  C  C  A
      110
P  T  Q  L  N  A  I  S  V  L  Y  F  D  D  S
      120
S  N  V  I  L  K  K  Y  R  N  M  V  V  R  A
      130
C  G  C  H.

```

5. The invention of claim 1 or 2 wherein the amino acid sequence of each said subunit comprises (Seq. ID No. 6):

OP1-16V

```

      30
      V  A  E  N  S
      40
S  S  D  Q  R  Q  A  C  K  K  H  E  L  Y  V
      50
S  F  R  D  L  G  W  Q  D  W  I  I  A  P  E
      60
G  Y  A  A  Y  Y  C  E  G  E  C  A  F  P  L
      70
N  S  Y  M  N  A  T  N  H  A  I  V  Q  T  L
      80
      90
V  H  F  I  N  P  E  T  V  P  K  P  C  C  A
      100
P  T  Q  L  N  A  I  S  V  L  Y  F  D  D  S
      110
      120
S  N  V  I  L  K  K  Y  R  N  M  V  V  R  A
      130
C  G  C  H.

```

6. The invention of claim 1 or 2 wherein the amino acid sequence of said subunit comprises (Seq. ID No.1):

OP1-18

```

1      10
S T G S K Q R S Q N R S K T P
      20      30
K N Q E A L R M A N V A E N S
      40
S S D Q R Q A C K K H E L Y V
      50      60
S F R D L G W Q D W I I A P E
      70
G Y A A Y Y C E G E C A F P L
      80      90
N S Y M N A T N H A I V Q T L
      100
V H F I N P E T V P K P C C A
      110      120
P T Q L N A I S V L Y F D D S
      130
S N V I L K K Y R N M V V R A
C G C H.

```

7. The invention of claim 1 or 2 wherein the amino acid sequence of each said subunit comprises (Seq. ID No. 2):

OP1-16S

```

      8      10
      S Q N R S K T P
      20      30
K N Q E A L R M A N V A E N S
      40
S S D Q R Q A C K K H E L Y V
      50      60
S F R D L G W Q D W I I A P E
      70
G Y A A Y Y C E G E C A F P L
      80      90
N S Y M N A T N H A I V Q T L
      100
V H F I N P E T V P K P C C A
      110      120
P T Q L N A I S V L Y F D D S
      130
S N V I L K K Y R N M V V R A
C G C H.

```

-77-

8. The invention of claim 1 or 2 wherein the amino acid sequence of each said subunit comprises (Seq. ID No. 3):

OP1-16L

```

                21                               30
                L R M A N V A E N S
                40
S S D Q R Q A C K K H E L Y V
                50                               60
S F R D L G W Q D W I I A P E
                70
G Y A A Y Y C E G E C A F P L
                80                               90
N S Y M N A T N H A I V Q T L
                100
V H F I N P E T V P K P C C A
                110                               120
P T Q L N A I S V L Y F D D S
                130
S N V I L K K Y R N M V V R A
C G C H.

```

9. The invention of claim 1 or 2 wherein the amino acid sequence of each of said subunit comprises (Seq. ID No. 4):

OP1-16M

```

                23                               30
                M A N V A E N S
                40
S S D Q R Q A C K K H E L Y V
                50                               60
S F R D L G W Q D W I I A P E
                70
G Y A A Y Y C E G E C A F P L
                80                               90
N S Y M N A T N H A I V Q T L
                100
V H F I N P E T V P K P C C A

```

```

      110                      120
P  T  Q  L  N  A  I  S  V  L  Y  F  D  D  S
      130
S  N  V  I  L  K  K  Y  R  N  M  V  V  R  A
C  G  C  H.

```

10. The invention of claim 1 or 2 wherein the amino acid sequence of each of said subunit comprises (Seq. ID No. 5):

OP1-16A

```

                        24                      30
                        A  N  V  A  E  N  S
                        40
S  S  D  Q  R  Q  A  C  K  K  H  E  L  Y  V
                        50                      60
S  F  R  D  L  G  W  Q  D  W  I  I  A  P  E
                        70
G  Y  A  A  Y  Y  C  E  G  E  C  A  F  P  L
                        80                      90
N  S  Y  M  N  A  T  N  H  A  I  V  Q  T  L
                        100
V  H  F  I  N  P  E  T  V  P  K  P  C  C  A
                        110                      120
P  T  Q  L  N  A  I  S  V  L  Y  F  D  D  S
                        130
S  N  V  I  L  K  K  Y  R  N  M  V  V  R  A
C  G  C  H.

```

11. The invention of claim 1 or 2 wherein said protein has an apparent molecular weight of about 30 kD when oxidized, as determined by comparison to molecular weight standards in SDS-polyacrylamide gel electrophoresis.

12. The invention of claim 1 or 2 wherein said protein has an apparent molecular weight of about 36 kD when oxidized, as determined by comparison to molecular weight standards in SDS-polyacrylamide gel electrophoresis.



13. The invention of claim 1 or 2 wherein said protein is unglycosylated.

14. The invention of claim 1 or 2 wherein said mammalian host cell is a chinese hamster ovary cell.

15. The invention of claim 1 or 2 wherein said mammalian host cell is a simian kidney cell.

16. A biocompatible, in vivo biodegradable matrix for implantation in a mammal comprising demineralized, delipidated, Type I insoluble bone collagen particles, depleted in noncollagenous protein, and treated with a hot aqueous medium having a temperature above about 37°C in an amount and for a time sufficient to alter the morphology of said particles.

17. The invention of claim 1 or 16 wherein said matrix is treated with a hot aqueous medium having a temperature within the range of 37°C to 65°C.

18. The invention of claim 1 or 16 wherein said matrix is treated with a hot aqueous medium having a temperature within the range of 45°C to 60°C.

19. The invention of claim 1 or 16 wherein said matrix is treated to increase the number of pores and micropits on said collagen particles at least 3-fold.

20. The invention of claim 1 or 16 wherein said matrix is treated to increase the number of pores and micropits on said collagen particles at least 10-fold.

21. The invention of claim 1 or 16 wherein said bone collagen particles comprise pores or micropits having a mean diameter within the range of 1 $\mu$ m to 100 $\mu$ m.

22. The invention of claim 1 or 16 wherein said collagen particles have a mean diameter within the range of 70 nm to 420 nm.

23. Osteogenic protein expressed from recombinant DNA in a mammalian host cell, said protein comprising two oxidized subunits constituting a dimeric species, the amino acid sequence of said subunits having sufficient homology with the amino acid sequence encoded by the gene of Figure 2 (Seq. ID No. 7) such that said dimeric species is capable of inducing bone or cartilage formation when implanted in a mammal in association with a matrix.

24. A biocompatible, in vivo biodegradable matrix for implantation in a mammal comprising demineralized, delipidated, Type-I insoluble bone collagen particles, depleted in a material comprising fraction 12 identified in Figure 8.

1/20




FIG. 1A




FIG. 1B

SUBSTITUTE SHEET

2/20

```

      10      20      30      40      50      60
GGTGCGGGCCCCGAGCCCCGAGCCCCGGGTAGCGCGTAGAGCCGGCGCGATGCACGTGCGC
                               SmaI                               M H V R
      70      80      90     100     110     120
TCACTGCGAGCTGCGGCGCCGCACAGCTTCGTGGCGCTCTGGGCACCCCTGTTCTGCTG
S L R A A A P H S F V A L W A P L F L L
      130     140     150     160     170     180
CGCTCCGCCCTGGCCGACTTCAGCCTGGACAACGAGGTGCACTCGAGCTTCATCCACCGG
R S A L A D F S L D N E V H S S F I H R

      190     200     210     220     230     240
CGCCTCCGCAGCCAGGAGCGGCGGGAGATGCAGCGGAGATCCTCTCCATTTTGGGCTTG
R L R S Q E R R E M Q R E I L S I L G L
      250     260     270     280     290     300
CCCCACCGCCCGCGCCCGCACCTCCAGGGCAAGCACAACCTCGGCACCCATGTTTCATGCTG
P H R P R P H L Q G K H N S A P M F M L
      310     320     330     340     350     360
GACCTGTACAACGCCATGGCGGTGGAGGAGGGCGGCGGCCCGGCCAGGGCTTCTCC
D L Y N A M A V E E G G G P G G Q G F S
      370     380     390     400     410     420
TACCCCTACAAGGCCGTCTTCAGTACCCAGGGCCCCCTCTGGCCAGCCTGCAAGATAGC
Y P Y K A V F S T Q G P P L A S L Q D S
      430     440     450     460     470     480
CATTTCTCACCAGCGCCGACATGGTCATGAGCTTCGTCAACCTCGTGGAAACATGACAAG
H F L T D A D M V M S F V N L V E H D K
      490     500     510     520     530     540
GAATTCTTCCACCCACGCTACCACCATCGAGAGTTCCGGTTTGATCTTTCCAAGATCCCA
E F F H P R Y H H R E F R F D L S K I P
      550     560     570     580     590     600
GAAGGGGAAGCTGTACGGCAGCCGAATTCGGATCTACAAGGACTACATCCGGGAACGC
E G E A V T A A E F R I Y K D Y I R E R
      610     620     630     640     650     660
TTCGACAATGAGACGTTCCGGATCAGCGTTTATCAGGTGCTCCAGGAGCACTTGGGCAGG
F D N E T F R I S V Y Q V L Q E H L G R
      670     680     690     700     710     720
GAATCGGATCTTCTCTGCTCGACAGCCGTACCCTCTGGGCCTCGGAGGAGGGCTGGCTG
E S D L F L L D S R T L W A S E E G W L
      730     740     750     760     770     780
GTGTTTGACATCACAGCCACCAGCAACCACTGGGTGGTCAATCCGCGGCACAACCTGGGC
V F D I T A T S N H W V V N P R H N L G
      790     800     810     820     830     840
CTGCAGCTCTCGGTGGAGACGCTGGATGGGCAGAGCATCAACCCCAAGTTGGCGGGCCTG
L Q L S V E T L D G Q S I N P K L A G L
      850     860     870     880     890     900
ATTGGGCGGCACGGGCCCCAGAACAAGCAGCCCTTCATGGTGGCTTCTTCAAGGCCACG
I G R H G P Q N K Q P F M V A F F K A T
      910     920     930     940     950     960
GAGGTCCACTTCCGCAGCATCCGGTCCACGGGGAGCAAACAGCGCAGCCAGAACCGCTCC
E V H F R S I R S T G S K Q R S Q N R S
                               └──────────┘
      970     980     990     1000     1010     1020
AAGACGCCCAAGAACCAGGAAGCCCTGCGGATGGCCAACGTGGCAGAGAACAGCAGCAGC
K T P K N Q E A L R M A N V A E N S S S
      1030     1040     1050     1060     1070     1080

```

*FIG. 2-1*

SUBSTITUTE SHEET



3/20

GACCAGAGGCAGGCCTGTAAGAAGCACGAGCTGTATGTCAGCTTCCGAGACCTGGGCTGG  
D Q R Q A C K K H E L Y V S F R D L G W  
1090 1100 1110 1120 1130 1140  
CAGGACTGGATCATCGCGCCTGAAGGCTACGCCGCCTACTACTGTGAGGGGGAGTGTGCC  
Q D W I I A P E G Y A A Y Y C E G E C A  
1150 1160 1170 1180 1190 1200  
TTCCTCTGAACTCCTACATGAACGCCACCAACCACGCCATCGTGCAGACGCTGGTCCAC  
F P L N S Y M N A T N H A I V Q T L V H  
1210 1220 1230 1240 1250 1260  
TTCATCAACCCGAAACGGTGCCCAAGCCCTGCTGTGCGCCCACGCAGCTCAATGCCATC  
F I N P E T V P K P C C A P T Q L N A I  
1270 1280 1290 1300 1310 1320  
TCCGTCCTCTACTTCGATGACAGCTCCAACGTCATCCTGAAGAAATACAGAAACATGGTG  
S V L Y F D D S S N V I L K K Y R N M V  
1330 1340 1350 1360 1370 1380  
GTCCGGGCTGTGGCTGCCACTAGCTCCTCCGAGAATTCAGACCCTTTGGGGCCAAGTTT  
V R A C G C H \*  
1390 1400 1410 1420 1430 1440  
TTCTGGATCCTCCATTGCTCGCCTTGCCAGGAACCAGCAGACCAACTGCCTTTTGTGAG  
BamH1  
1450 1460 1470 1480 1490 1500  
ACCTTCCCCTCCCTATCCCCAACTTTAAAGGTGTGAGAGTATTAGGAAACATGAGCAGCA  
1510 1520 1530 1540 1550 1560  
TATGGCTTTTGATCAGTTTTTTCAGTGGCAGCATCCAATGAACAAGATCCTACAAGCTGTG  
1570 1580 1590 1600 1610 1620  
CAGGCAAAACCTAGCAGGAAAAAACAACGCATAAAGAAAAATGGCCGGGCCAGGTCA  
1630 1640 1650 1660 1670 1680  
TTGGCTGGGAAGTCTCAGCCATGCACGGAAGTTCGTTTCCAGAGGTAATTATGAGCGCCTAC  
1690 1700 1710 1720 1730 1740  
CAGCCAGGCCACCCAGCCGTGGGAGGAAGGGGGCGTGGCAAGGGGTGGGCACATTGGTGT  
1750 1760 1770 1780 1790 1800  
CTGTGCGAAAGGAAATTGACCCGGAAGTTCTCTGTAATAAATGTCACAATAAACGAATG  
1810 1820  
AATGAAAAAAAAAAAAAAAAA



*FIG. 2-2*

SUBSTITUTE SHEET



4/20

**FIG. 3A****FIG. 3B**

SUBSTITUTE SHEET



SUBSTITUTE SHEET

**FIG. 3E****FIG. 3F**

SUBSTITUTE SHEET



7/20




FIG. 4

8/20




FIG. 5A-I




FIG. 5B-I




FIG. 5C-I

9/20




FIG. 5A-2




FIG. 5B-2






FIG. 5C-2


10/20

**FIG. 6**

11/20




**FIG. 7A**




**FIG. 7B**

**SUBSTITUTE SHEET**

12/20



**FIG. 7C**



**FIG. 7D** SUBSTITUTE SHEET

13/20




FIG. 8

14/20




FIG. 9A




FIG. 9B


SUBSTITUTE SHEET



15/20




**FIG. 10A**




**FIG. 10B**

**SUBSTITUTE SHEET**



**FIG. 10C**




**FIG. 10D**

**SUBSTITUTE SHEET**

17/20



**FIG. 10E**



**FIG. 10F**

**SUBSTITUTE SHEET**

18/20





FIG. II

SUBSTITUTE SHEET






FIG. 13A





FIG. 13B

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/US90/05903

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5): C07K 15/00, 15/06, 15/14, 17/02; C09H 1/02; A61K 37/12 U.S. CL. 530/350, 356, 840; 514/2, 21; 424/423, 424, 426; 128/DIG 8		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
U.S.	530/350, 356, 840; 514/2, 21; 424/423, 424, 426 128/DIG 8	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
Y	US, A, 4,394,370 (JEFFERIES) 19 JULY 1983 See column 3, lines 10-25 for the demineralized bone powder and Example 1 for preparation of the matrix.	1-22 & 24
Y	EP, A, 0 148 155 (SEN) 10 JULY 1985 See page 18 for production of mineralized bone powder.	1-22 & 24
Y	EP, A, 0 182 483 (NATHAN) 28 MAY 1986 See page 9, line 31 to page 10, line 23 for production of demineralized bone powder.	1-22 & 24
Y	WO, A, W088/00205 (WANG) 14 JANUARY 1988 See page 11, lines 2-19 for production of a matrix and page 12, line 12 to page 13, line 27 for production of matrix material.	1-24
Y	Proc. Natl. Acad. Sci., USA, Vol. 80, November 1983, (SAMPATH), "Homology of bone-inductive proteins from human, monkey, bovine and rat extracellular matrix" pages 6591-6595. See "Materials and Methods" for production of the matrix.	1-22 & 24
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
13 DECEMBER 1990		05 FEB 1991
International Searching Authority		Signature of Authorized Officer
ISA/US		 Nathan M. Nutter

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	Proc. Natl. Acad. Sci., Vol. 78, No. 12, USA, December 1981 (SAMPATH), "Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation". Pages 7599-7603. See page 7599 "Preparation of Demineralized Bone", See entire section.	1-22 & 24
A	US, A, 4,172,128 (THIELE) 23 OCTOBER 1979	1-24
A	US, A, 4,294,753 (URIST) 13 OCTOBER 1981	1-24
A	US, A, 4,434,094 (SEYEDIN) 28 FEBRUARY 1984	1-24
A	US, A, 4,563,350 (NATHAN) 07 JANUARY 1986	1-24
A	US, A, 4,563,489 (URIST) 07 JANUARY 1986	1-24
A	US, A, 4,657,548 (NICHOLS) 14 APRIL 1987	1-24
A	US, A, 4,703,108 (SILVER) 27 OCTOBER 1987	1-24
A	US, A, 4,725,671 (CHU) 16 FEBRUARY 1988	1-24
A	US, A, 4,789,663 (WALLACE) 06 DECEMBER 1988	1-24
A	US, A, 4,812,120 (FLANAGAN) 14 MARCH 1989	1-24
A	US, A, 4,824,939 (SIMPSON) 25 APRIL 1989	1-24
A	US, A, 4,837,285 (BERG) 06 JUNE 1989	1-24
A,P	US, A, 4,894,441 (MENICAGLI) 16 JANUARY 1990	1-24
A	WO, A, W086/00526 (CAPLAN) 30 JANUARY 1986	1-24
A,P	WO, A, W089/09605 (BENTZ) 19 OCTOBER 1989	23
A,P	WO, A, W089/10409 (WANG) 02 NOVEMBER 1989	1-24
A	EP, A, 0 128 041 (BAYLINK) 12 DECEMBER 1984	23
A	EP, A, 0 169 001 (SABELMAN) 22 JANUARY 1986	1-22 & 24
A	EP, A, 0 169 016 (SEYEDIN) 22 JANUARY 1986	23
A	EP, A, 0 212 474 (URIST) 04 MARCH 1987	1-24
A	EP, A, 0 230 647 (FUJIOKA) 05 AUGUST 1987	1-24
A	EP, A, 0 309 241 (CHU) 29 MARCH 1989	1-24
A	Collagen Research, Vol. 1/1981 A.H. Reddi "Cell Biology and Biochemistry of Endochondral Bone Development" pages 209-226.	1-24



## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup>	Relevant to Claim No <sup>18</sup>
A	The Lancet, May 2, 1981, Julie Glowacki "Application of the Biological Principle of Induced Osteogenesis for Craniofacial Defects" pages 959-963.	1-24
A	Journal of Biomedical Materials Research, Vol. 19, 1985, A.H. Reddi "Implant-stimulated interface reactions during collagenous bone matrix-induced bone formation" pages 233-239.	1-24
A	Clinical Orthopaedics and Related Research Number 187, July/August 1984, Marshall R. Urist " $\beta$ -tricalcium Phosphate Delivery System for Bone Morphogenetic Protein" pages 277-280.	1-24
A	Biotechnology and Bioengineering. Vol. XXVI, 1984 Janie M. strand "A Modified Matrix Perfusion-Micro-carrier Bead Cell Culture System. I Adaption of the Matrix Perfusion System for Growth of Human Foreskin Fibroblasts" pages 503-507.	1-24
A	Clinical Orthopaedics and Related Research, Number 232, July 1988 Stephan D. Cook "Hydroxyapatite-Coated Titanium for Orthopaedic Implant Applications" pages 225-243.	1-24
A	Journal of Arthroplasty, Vol 2, No. 2, June 1987 Myron Spector "Historical Review of Porous Coated Implants" pages 163-177.	1-24
A	Int. J. Orla Maxillofac. Surg. Vol. 17, 1988 J.R. Deatherage "A review of matrix-induced osteogenesis with special reference to its potential use in craniofacial surgery" pages 395-399.	1-24
A	J. Bone JointSurg. Vol. 70-B, 1988 Per Aspenberg "Failure of Bone Induction by Bone Matrix in Adult Monkeys" pages 625-627.	1-24